

## CURRICULUM VITAE

First name	<b>Francesco</b>
Surname	<b>Bertoni</b>
Date of birth	August 5th, 1969
Place of birth	Rome, Italy
Citizenship	Italian
Marital status	Married, two daughters
Work address	Lymphoma Genomics Group, head Institute of Oncology Research, deputy director, Faculty of Biomedical Sciences, Università della Svizzera italiana (USI) via Francesco Chiesa 5, 6500 Bellinzona Switzerland
phone	+41 58 666 72 06
E-mail	frbertoni@mac.com, francesco.bertoni@ior.usi.ch
ORCID	<a href="https://orcid.org/0000-0001-5637-8983">https://orcid.org/0000-0001-5637-8983</a>

### EDUCATIONAL BACKGROUND

July 26 <sup>th</sup> , 1994	Medical Doctor, summa cum laude, State University of Milan, Italy, with degree thesis " <i>Linfomi non Hodgkin a grado intermedio-alto di malignità: strategie terapeutiche ed esperienza presso l'Istituto San Raffaele</i> "
------------------------------	--

### SPECIALITY BOARD

November 10 <sup>th</sup> , 1998	Post-graduated in Oncology summa cum laude, Specialty School of Oncology, State University of Milan, Italy, with degree thesis " <i>Analisi molecolare del riarrangiamento genico delle catene pesanti delle immunoglobuline nel linfoma primitivo gastrico a cellule B della zona marginale (di tipo MALT)</i> " (Milan, November 10 <sup>th</sup> , 1998)
----------------------------------	---

### ADDITIONAL EDUCATION AND QUALIFICATIONS

11/2021	GCP Sponsor-Investigator level, CTU-EOC, Lugano, Switzerland
10/2021	GCP Investigator level, CTU-EOC, Lugano, Switzerland
Since 02/2019	Adjunct Professor, Faculty of Biomedical Sciences, Università della Svizzera italiana (USI), Lugano, Switzerland
Since 07/2017	Italian "Abilitazione Scientifica Nazionale alle funzioni di Professore Universitario di Prima Fascia", Bando D.D. 1532/2016, Settore Concorsuale 06/D3 "Malattie del Sangue, Oncologia e Reumatologia" (20/7/2017-20/7/2029)
06/2015	FELASA Category B LTK module 1, University of Zurich, Zurich, Switzerland

### RESEARCH TOPICS

Development of anti-lymphoma compounds  
Lymphoma genomics

### WORKING EXPERIENCES

<b>Since 03/2020</b>	Research Consultant, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
<b>Since 09/2011</b>	Group Leader of the Lymphoma Genomics Group; Head of the Lymphoma and Genomics Research Program; Deputy Director of the Institute of Oncology Research, Bellinzona, Switzerland
4/2007- 9/2011	Deputy Director of Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland

03/2003-09/2011	Head of the Functional Genomics, Lymphoma Unit, Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland
10/1999-02/2003	Department of Experimental Haematology (Finbarr E. Cotter), The Barts and The London - Queen Mary's School of Medicine and Dentistry, London, UK
04-09/1999	Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland (Franco Cavalli), c/o Ospedale Regionale, Locarno, Switzerland
04/1998-03/1999	Molecular Pharmacology Unit (Massimo Broggin), Department of Oncology (Maurizio D'Incalci), "Mario Negri" Institute of Pharmacological Research, Milan, Italy
01-04/1998	Molecular Haematology Unit (Finbarr E. Cotter), Institute of Child Health, University College London Medical School, London, United Kingdom
01/1996-12/1997	Medical Oncology Department and Bone Marrow Transplantation Laboratory (Emanuele Zucca), Servizio Oncologico Cantonale (Franco Cavalli), Ospedale Regionale, Locarno, Switzerland
08/1995	Medical Oncology Department, Servizio Oncologico Cantonale (Franco Cavalli), Ospedale San Giovanni, Bellinzona, Switzerland
02-12/1995	Service of Medical Oncology (Paolo Foa) at the 1st Postgraduate School of Haematology (Anna Teresa Maiolo), State University, Ospedale Maggiore, Milan, Italy
11/1991-1/1995	Division of Medicine II (Claudio Rugarli), Istituto Scientifico San Raffaele, Milan, Italy

## **ADDITIONAL RESPONSIBILITIES**

### On-going

Since 09/2024	Member of the Academic Advisory Committee of the Regional Alliance of Lymphoma Subspecialty for Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Since 02/2024	Ex officio member of the SIB Swiss Institute of Bioinformatics Foundation Council
Since 12/2022	Core Team Member, Project Group Developmental Therapeutics of the Swiss Group for Clinical Cancer Research (SAKK)
Since 04/2022	Member, Scientific Advisory Board, International Extranodal Lymphoma Study Group (IELSG)
Since 06/2022	Member of the USI Startup Centre Scientific Board
Since 01/2022	Member of the Scientific Committee of the Swiss Cancer League and Swiss Cancer Research foundation
Since 01/2022	Member of the Editorial Board, Annals of Lymphoma.
Since 01/2022	Mentor, College of the European School of Oncology (ESCO)
Since 2021	Chairman, Organizing Committee, International Conference on Malignant Lymphoma (17-ICML)
Since 10/2019	Member of the Steering Committee, Programma Formazioni di Ematologia IOSI
Since 08/2020	Associate-Editor, Exploration of Targeted Anti-tumor Therapy
Since 10/2018	Ambassador of the European Association for Cancer Research
Since 12/2013	Member of the Editorial Board, Cancer Biology & Medicine

### Past

01/2008-12/2025	Editor-in-Chief, Hematological Oncology
01/2022-03/2025	President, Project Group Lymphoma of the Swiss Group for Clinical Cancer Research (SAKK)
06/2021-12/2025	Member of the Scientific Advisory Board of the Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain
10/2018-05/2025	Ambassador of the European Association for Cancer Research
2024	Co-chair of the Scientific Program Committee of the 4 <sup>th</sup> AACR International Meeting "Advances in Malignant Lymphoma"
2022	Co-chair of the Scientific Program Committee of the 3 <sup>rd</sup> AACR International Meeting "Advances in Malignant Lymphoma"
2020	Co-chair of the Scientific Program Committee of the 2 <sup>nd</sup> AACR International Meeting "Advances in Malignant Lymphoma"
6/2016-12/2021	Vice-president of the Project Group Lymphoma of the Swiss Group for Clinical Cancer Research (SAKK)

01/2020-03/2022	Member of the Editorial Board, <i>Cancers</i>
2/2020-3/2022	Member of the Editorial Board, <i>Clinical Epigenetics</i>
2012-2019	Authorized Thesis Director, UNIL Université de Lausanne, Lausanne, Switzerland
2019-2021	President, Organizing Committee, 16 <sup>th</sup> International Conference on Malignant Lymphoma (16-ICML)
2018	Co-chair of the Scientific Program Committee of the 1 <sup>st</sup> AACR International Meeting “Advances in Malignant Lymphoma”
2017-2019	Member of the Organizing Committee, 15 <sup>th</sup> International Conference on Malignant Lymphoma (15-ICML)
2015-2017	Member of the Organizing Committee, 14 <sup>th</sup> International Conference on Malignant Lymphoma (14-ICML)
2013-2015	Member of the Organizing Committee, 13 <sup>th</sup> International Conference on Malignant Lymphoma (13-ICML)
2013-2014	Lymphoma co-Editor, Elsevier Ltd website “Leukaemia & Lymphoma”
2011-2013	Member of the Organizing Committee, 12 <sup>th</sup> International Conference on Malignant Lymphoma (12-ICML)
2009-2011	Member of the Advisory Board, 11 <sup>th</sup> International Conference on Malignant Lymphoma (11-ICML)
6/2007-04/2023	Member of the Editorial Board, <i>Leukemia and Lymphoma</i>
2/2005-12/2007	Associate-Editor, <i>Hematological Oncology</i>

Reviewer of manuscripts for various journals, including *American Journal of Pathology*, *Annals of Oncology*, *Blood*, *Blood Advances*, *BMC Cancer*, *British Journal of Haematology*, *Cancer*, *Cancer Discovery*, *Clinical Cancer Research*, *Clinical Lymphoma*, *European Journal of Cancer*, *Haematologica*, *International Journal of Cancer*, *Journal of Pathology*, *Journal of Clinical Pathology*, *Lancet*, *Lancet Haematology*, *Leukemia*, *Leukemia and Lymphoma*, *Molecular Cancer Therapeutics*.

Guest Editor for special issues for *Annals of Lymphoma*, *European Journal of Medicinal Chemistry* and *Exploration of Targeted Anti-tumor Therapy*.

Reviewer of national and international grant applications (including acting as member of the Scientific Evaluation Committee of the National Cancer Institute of France), and of abstracts submitted to international conferences.

## MEMBERSHIPS

American Association for Cancer Research (AACR); Associazione Italiana di Oncologia Medica (AIOM); American Society of Clinical Oncology (ASCO); American Society of Hematology (ASH); American Society for Pharmacology and Experimental Therapeutics (ASPET); British Society of Haematology (BSH); European Association for Cancer Research (EACR); European Hematology Association (EHA); European Society for Medical Oncology (ESMO); European Organisation for Research and Treatment of Cancer (EORTC); International Extranodal Lymphoma Study Group (IELSG); Swiss Group for Clinical Cancer Research (SAKK); Royal Society of Chemistry (RCS).

## PATENTS

- Sartori G, Cavalli A, Cascione L, Matkovic M, Bertoni F. Use of olfactory receptor OR13A1 ligands in the treatment of lymphomas. EP 4241766A1. Filing date: March 7th 2022. Applicant: Fondazione Per L'istituto Oncologico Di Ricerca (IOR) & Fondazione per l'Istituto di Ricerca in Biomedicina (IRB).
- Zimmerman J, Bertoni F, Arribas JA. Pharmaceutical combinations for treating cancer. WO2023285677A1. Filing Date: July 15, 2022. Application filed by SPEXIS AG.
- Spohn G, Mehli F, Schmidt A, Bertoni F, Spriano F, Sartori G. L1CAM binding molecules for treating hematological malignancy diseases. WO/2025/068389. Publication Date: April 3rd, 2025. Filing Date: September 26, 2024. Application filed by ELTHERA AG.
- Mensah A, Spriano F, Pietra C, Lovati E, Bertoni F. Methods of using pracinostat in synergistic combinations to treat lymphoma. Application Number 63/091,741 Filing Date: October 14, 2020. Application filed by Helsinn.
- Gaudio E, Bertoni F, Pazzi N, Guala M. New compounds with enhanced anti-tumor effects. WO2019185117A1. Filing date: March 26<sup>th</sup> 2018. Applicant: Fondazione Per L'istituto Oncologico Di Ricerca (IOR).
- Zammarchi F, Bertoni F. Combination therapy. PCT/EP2019/073212, WO/2020/043878. Publication Date: March 5<sup>th</sup> 2020. Current Assignee ADC Therapeutics SA MedImmune Ltd.
- Zammarchi F, Bertoni F. Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent. PCT/EP2020/065879, WO2020249527A1. Publication Date: December 17th, 2020. Application filed by Adc Therapeutics Sa, Medimmune Limited.
- Zammarchi F, Bertoni F. Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent. WO2020249528A1. Publication Date: December 17th, 2020. Application filed by Adc Therapeutics Sa, Medimmune Limited.
- Binaschi M, Bigioni M, Merlino G, Simonelli C, Bertoni F, Pellacani A. M. Pharmaceuticals combinations comprising an anti-LY75 antibody. PCT/EP2018/055939. Publication Date: September 13<sup>th</sup> 2018. Filing date: March 9<sup>th</sup> 2018. Applicant: Berlin-Chemi AG.
- Marques CS, Busto N, Gaudio E, Bertoni F, Burke AJ. Novel N-(1,2,3-Triazolmethyl)Isatin and N-(1,2,3-Triazolmethyl)-3-Hydroxy-3-aryloxindoles with Cytotoxic and Anti-Tumor Activity. EP3400938B1/PTA 11006317. Filing date: 2018-04-18. Original Assignee: Universidad de Evora.

- Bertoni F, Romanelli A, Sloss C. Methods for improving anti-cd37 immunoconjugate therapy. PCT/IB2017/056841. WO2018083633A1. Priority date: 2016-11-02. Original Assignee: Debiopharm International, S.A.
- Riveiro ME, Raymond E, Bertoni F. Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds. WO2015189814 A1. Priority date: 2014-06-13. Publication date: 2015-12-17. Original Assignee: ONCOETHIX GmbH.
- Bertoni F, Inghirami G. Method of treating diffuse large B-cell lymphoma (DLBCL) using a BET-bromodomain inhibitor. PCT/EP2014/002164, WO2015018521 A1. Priority date: 2013-08-06. Publication date: 2015-02-12. Original Assignee: Oncoethix Sa.
- Bertoni F, Inghirami G. A BET-BRD inhibitor represents a novel agent for ALK positive anaplastic large cell lymphoma. WO2015018520 A1. Priority date: 2013-08-06. Publication date: 2015-02-12. Original Assignee: Oncoethix Sa.
- Bertoni F, Inghirami G. Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large B-cell lymphoma (DLBCL). PCT/EP2014/002163, WO2015018522 A1. Priority date: 2013-08-06. Publication date: 2015-02-12. Original Assignee: Oncoethix Sa.
- Bertoni F, Bonetti P. Method of treating lymphoma using thienotriazolodiazepine compounds. PCT/EP2013/063313, WO2014001356 A1. Priority date: 2012-06-25. Publication date: 2015-04-29. Original Assignee: Oncoethix Sa.
- Bertoni F. Method of treating lymphoma using thienotriazolodiazepine compounds. PCT/EP2015/069092, US15504722. Priority date: 2014-08-19. Publication date: 2015-08-19. Original Assignee: Original Assignee: ONCOETHIX GmbH.
- Bertoni F, Noel K. Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds. PCT/US2015/028835, WO2015168587 A1. Priority date: 2014-05-02. Publication date: Nov 5, 2015. Original Assignee: Oncoethix Sa.
- Simon G, Giannella-Borradori A, & Bertoni F. Roscovitine treatment of mantle cell lymphoma. PCT/GB2004/004700, WO2005044274 A1. Priority date: 2003-11-06. Publication date: 2005-05-19. Original Assignee: Cyclacel Limited.

## THESIS SUPERVISION

### PhD theses:

- "Identification and characterization of enhancer RNAs in marginal zone lymphoma and in mantle cell lymphoma" by Francesca Guidetti, USI, Lugano, Switzerland (**on-going**);
- "Genetic CRISPRi Screening Identifies Functional Roles of Enhancer RNAs in Refractory Diffuse Large B Cell Lymphoma " by Nicolas Munz, USI, Lugano, Switzerland, **2025**;
- "Investigation of the role of mutated *TET2* in marginal zone lymphomas" by Fangwen Zhang, USI, Lugano, Switzerland, **2025**;
- "Preclinical evaluation of the ETS inhibitors YK-4-279 and TK-216 in lymphoma" by Filippo Spriano, UNIL, Lausanne, Switzerland, **2021**;
- "Role of ETS1 in the biology of ABC DLBCL" by Valdemar Priebe, UNIL, Lausanne, Switzerland, **2018**;
- "Epigenome as a therapeutic target for lymphomas" by Elena Bernasconi, UNIL, Lausanne, Switzerland, **2017**;
- "The contribution of genomic aberration to the pathogenesis of mature B-cell lymphomas" by Monica Testoni, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, **2014**;
- "Anaplastic large cell lymphoma: one or more entities?" by Michela Boi, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, **2013**;
- "Genomic profiling of diffuse large B-cell lymphomas" by Marta Scandurra, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, **2010**;
- "Stochastic methods in cancer research. Applications to genomics and angiogenesis" by Paola Rancoita, Universita' degli Studi di Milano, Dipartimento di Matematica, Milan, Italy;
- "Genomic profiling of B-cell lymphoid neoplasms" by Giulia Poretti, Universite de Geneve - Faculte des Sciences, Geneva, Switzerland, **2009**;

### Graduation theses:

- "Mechanisms of secondary resistance to PI3K/BCL2 inhibitors in marginal zone lymphoma", by Federica Fuzio, Corso di Laurea Magistrale in Biotecnologie del Farmaco, Universita' degli Studi di Milano, Facolta' di Scienze del Farmaco, Milan, Italy, **2024**; "Olfactory receptor 13A1: a novel prospective therapeutic target in lymphoma malignancies", by Alessandro Ghiringhelli, Corso di Laurea Magistrale in Biotecnologie del Farmaco, Universita' degli Studi di Milano, Facolta' di Scienze del Farmaco, Milan, Italy, **2024**; "Pre-clinical characterization of an antibody-drug conjugate (ADC) targeting CD19 in combination with targeted agents in cellular models of diffuse large B cell lymphoma (DLBCL)", by Eleonora Cannas, Corso di Laurea in Biomedical Sciences, Universita' degli Studi dell'Insubria, Dipartimento di Biotecnologie e Scienze della Vita, Varese, Italy, **2022**; "Antitumoral activity of PIM inhibition in cellular models of diffuse large B-cell lymphoma", by Chiara Folloni, Corso di laurea in Scienze e Sicurezza Chimico-Tossicologiche dell'Ambiente, Universita' degli Studi di Milano, Facolta' di Scienze del Farmaco, Milan, Italy, **2021**; "Preclinical evaluation of novel CREBBP/EP300 PROTACs as anti-lymphoma agents", by Giorgia Risi, Laurea Specialistica in Scienze biotecnologiche veterinarie, Universita' degli Studi di Milano, Facoltà di Medicina Veterinaria, Milan, Italy, **2021**; "Antiproliferative activity induced by the dual pharmacological inhibition of ATR and PI3K in non-Hodgkin lymphoma cell lines", by Michele Mascia, Corso di laurea magistrale in Biotecnologie sanitarie mediche e veterinarie, Dipartimento di Veterinaria, Universita' di Sassari, Sassari Italy, **2020**; "Valutazione dell'attività antitumorale di inibitori del canale del potassio Kv1.3 in modelli cellulari di linfoma umano", by Marco Bernasconi, Corso di Laurea in Biotecnologie, Universita' degli Studi dell'Insubria, Dipartimento di Biotecnologie e Scienze della Vita, Varese, Italy, **2020**; "Pre-clinical characterization of three novel antibody-drug conjugates in human lymphoma cell lines", by Lorenzo Scalise, Corso di Laurea in Biotecnologie Molecolari e Industriali, Universita' degli Studi dell'Insubria, Dipartimento di Scienze Teoriche e Applicate, Varese, Italy, **2019**; "Valutazione preclinica di un nuovo inibitore delle proteine BTK (farmaco 1) in singolo e in combinazione con altre molecole in modelli di linfoma umano", by Elisabetta Curti, Laurea in Scienze e tecnologie Biologiche, Universita' degli Studi dell'Insubria, Varese, Italy, **2018**; "Pre-clinical characterization of a new antibody-drug conjugate (ADC) in cellular models of diffuse large B-cell lymphoma (DLBCL)" by Francesca Guidetti, Laurea in Biologia Applicata alla Ricerca Laurea in Biologia Applicata alla Ricerca, Universita' degli Studi dell'Insubria, Varese, Italy, **2017**; "Valutazione preclinica di un nuovo inibitore delle proteine BTK (farmaco 1) in singolo e in combinazione con altre molecole in modelli di linfoma umano" by Elisabetta Curti, Laurea in Scienze e tecnologie Biologiche, Universita' degli Studi dell'Insubria, Varese, Italy, **2017**; "Novel BTK and PI3K-delta inhibitors show pre-clinical activity in combination in B-cell tumors", by Altea Targa, Laurea Specialistica in Scienze biotecnologiche veterinarie, Universita' degli Studi di Milano, Facoltà di Medicina Veterinaria, Milan, Italy, **2015**; "A MEK1/2

inhibitor affects proliferation of human non-Hodgkin lymphoma cell lines”, by Chiara Barassi, Laurea Magistrale in Biologia Sperimentale e Applicata, Università degli Studi di Pavia, Pavia, Italy, **2014**; “Pre-Clinical evaluation of a new anti-lymphoma agent”, by Giovanna Panepinto, Laurea Specialistica in Scienze biotecnologiche veterinarie, Università degli Studi di Milano, Facoltà di Scienze Matematiche Fisiche e Naturali, Milan, Italy, **2013**; “Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and TP53 pathway and differ from de-novo diffuse large B-cell lymphoma”, by Marco Albonico, Laurea Specialistica in Scienze biotecnologiche veterinarie, Università degli Studi di Milano, Facoltà di Scienze Matematiche Fisiche e Naturali, Milan, Italy, **2013**; “Valutazione del gene A20 come nuovo gene soppressore tumorale nei linfomi della zona marginale”, by Silvana Branca, Laurea Specialistica in Biologia Applicata alla Ricerca Biomedica, Università degli Studi di Milano, Facoltà di Scienze Matematiche Fisiche e Naturali, Milan, Italy, **2010**; “Evaluation of candidate cancer genes in diffuse large B-cell lymphomas” by Monica Testoni, Corso di Laurea in Biologia e Scienze Biologiche Università di Milano Bicocca, Milan, Italy, **2010**; “Tirosin chinasi Syk: nuovo target terapeutico in linfomi aggressivi di tipo B” by Sara Pesenti, Laurea Specialistica in Biotecnologie Industriali e Biocatalisi, Facoltà di Scienze Matematiche, Fisiche e Naturali, Università degli Studi dell’Insubria, Varese, Italy, **2007**

- **Diploma thesis:** “Tyrosine kinase Syk inhibitors in mantle cell lymphoma and in diffuse large B cell lymphomas: in vitro activity and mechanism of action” by Anna Sasso, ETH - Swiss Federal Institute of Technology Zurich, **2006**

## MAIN GRANTS

Title	Grant #	start	end	Amount given	Role
Wiskott-Aldrich Syndrome Protein in Lymphomagenesis: Unraveling the Interplay Between Somatic Mutations, B-cell Receptor Signaling and Actin Dynamics	Swiss National Science Foundation (SNSF) 310030E_238053	01/2026	12/2028	CHF 730'857	main applicant
Molecular and Cellular Characterization of MALT Lymphoma Across Anatomical Sites: Integrative Transcriptomic and Epigenetic Approaches	Swiss National Science Foundation (SNSF) 10.007.245	10/2025	09/2029	CHF 989'900	Project partner
Resistance to BTK Inhibitors in B-cell lymphomas: ERBB4 signalling and therapeutic vulnerabilities	Swiss Cancer Research KFS-6384-02-2025	08-2025	07-2028	CHF 358,092	main applicant
Overcoming B-cell lymphoma resistance to CD19-CAR T cells using combination therapies to enhance and sustain CD19 expression	Swiss National Science Foundation (SNSF) 310030_220070 / 1	2024	2027	CHF 602,885	Co-applicant
IELSG52: integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma	KFS-5778-02-2023	2023	2027	CHF 306,400	Co-applicant
First-in-class oncology therapeutics for hematological cancers targeting Wiskott Aldrich syndrome protein	Eurostars Project E12829 HEMATO-WASP	2023	2025	CHF 332,104 (to FB)	Project partner
NCCR RNA & disease: The role of RNA biology in disease mechanisms (phase III)	Swiss National Science Foundation (SNSF) 51NF40_205601	2022	2026	CHF 1,463,913 (total)	Co-applicant
G protein-coupled receptors of the olfactory receptors' family provide novel therapeutic opportunities against lymphoma cells	Swiss Cancer Research KFS-5502-02-2022	08-2022	07-2025	CHF 341,400,828	main applicant
Evaluation of non-ATP competitive PI3K $\delta$ inhibition with IOA-244 in the treatment of lymphoma	Innosuisse 55179.1 IP-LS	08-2021	08-2023	CHF 596,828	academic research partner
Enhancer RNAs in B cell lymphomas	Swiss National Science Foundation (SNSF) 310030_197466	11-2020	10-2024	CHF 792,257	main applicant
Anti-L1CAM antibody therapy for rare diseases	Innosuisse 39947.1 IP-LS	11-2020	11-2022	CHF 683,987.84	academic research partner
Inhibitory effect of anti JAM-C antibodies in cell lines resistant to conventional pharmacological therapy	Innosuisse 48973.1 INNO-LS	09-2020	03-2021	CHF 15,000	academic research partner
Development of a microfluidic platform for real-time detection of SARS-CoV-2 virus based on multifunctional silica membrane biosensors	SNSF NRP 78 Covid-19 #198265	10-2020	09-2022	CHF 1,098,174	co-applicant
The PI3K $\delta$ inhibitor IOA-244 as an immuno-regulator for the treatment of lymphoma	Innosuisse 43889.1 INNO-LS	05-2020	05-2021	CHF 15,000	academic research partner
Transcriptome analysis to improve the outcome prediction and to identify novel therapeutics targets in follicular lymphoma patients	Fondazione Ticinese per la Ricerca sul Cancro	06-2020	05-2021	CHF 80,000	main applicant
An integrated approach to identify the mechanism of resistance to copanlisib and venetoclax in marginal zone lymphoma	Oncosuisse KFS-4727-02-2019	08-2019	07-2022	CHF 360,305	main applicant
Genetic screening of enhancer RNAs to understand their causative biological role in refractory diffuse large B cell lymphoma	NCCR RNA & Disease	05-2020	04-2023	CHF 180,000	main applicant
Characterization of specific enhancer RNAs involved in ibrutinib resistance mechanism in marginal zone lymphoma	SNSF Sparks CRSK-3_190808	03-2020	02-2021	CHF 100,000	co-applicant
Ultra-conserved long non-coding RNAs in B-cell lymphoma	Oncosuisse KFS-4713-02-2019	08-2019	07-2021	CHF 180,600	co-applicant

Finding a way to by-pass the resistance to PI3K inhibitors in marginal zone lymphomas	Fondazione Ticinese per la Ricerca sul Cancro	06-2019	05-2020	CHF 60,000	main applicant
Multilayer model for personalized risk stratification of follicular lymphoma patients	Oncosuisse KFS-4395-02-2018	09-2018	08-2021	CHF 330,800	co-applicant
CA18238 - European transdisciplinary networking platform for marine biotechnology	COST (European Cooperation in Science and Technology)	10-2019	10-2023	-	Management Committee member
Surface expression of L1 cell adhesion molecule (L1CAM) in hematological malignancies	Innocheque 34266.1 INNO-LS	01-2019	03-2019	CHF 14,800	academic research partner
An implantable device to tailor treatment in patients with lymphoma	Fondazione Leonardo	04-2017	03-2019	CHF 280,000	main applicant
Novel small molecule targets FLI1 in lymphoma and T-ALL	Leukemia & Lymphoma Society #6521-17	10-2016	09-2019	USD 600,000	main applicant
Targeted agents in splenic marginal zone lymphoma: mechanisms of resistance and new combinations	SNSF 31003A_163232/1	10-2015	09-2018	CHF 429,800	main applicant
Characterization of FLI1 as an oncogene and therapeutic target in diffuse large B-cell lymphomas	Oncosuisse KLS-3580-02-2015	08-2015	07-2018	CHF 359,800	main applicant
An international phase III multicenter, randomized study with lenalidomide maintenance versus observation after intensified induction regimen containing rituximab followed by high dose chemotherapy and autologous stem cell transplantation as first line treatment in adult patients with advanced mantle cell lymphoma: Identification of DNA and methylation changes associated with the clinical outcome	Oncosuisse KLS-3636-02-2015	08-2015	07-2017	CHF 115,800	co-applicant
Identificazione di nuovi meccanismi patogenetici e nuove terapie in linfomi aggressivi pediatrici	Fondazione Gelu	10-2014	9-2017	CHF 650,000	main applicant
Development of a Center of Excellence in Lymphomas at IOSI	Nelia and Amadeus Barletta Foundation	10-2011	09-2014	CHF 1,500,000	main applicant
Functional analysis of altered transcriptional pathways in diffuse large B-cell lymphoma of the ABC subtype	SNSF Sinergia 147620	8-2013	7-2016	CHF 1,500,000	co-applicant
Steiner Trees for Functional Analysis in Cancer System Biology	SNSF 147138	4-2013	4-2016	CHF 153,900	co-applicant
Anaplastic Large Cell Lymphoma: One Or More Entities?	Anna Lisa Stiftung	4-2012	3-2014	CHF 100,000	main applicant
Functional characterization of an 11q24.3 gain contributing to the pathogenesis of diffuse large B cell lymphoma by blocking B-cell maturation	San Salvatore Foundation	12-2011	11-2013	CHF 231,000	main applicant
The methylome of splenic marginal zone lymphoma: an integration of epigenetic, genetic and clinical data	Jubiläumstiftung der Schweizerischen Lebensversicherungs- und Rentenanstalt für Volksgesundheit und medizinische Forschung (SwissLife)	04-2011	07-2014	CHF 60,000	main applicant
The methylome of splenic marginal zone lymphoma: an integration of epigenetic, genetic and clinical data	Fondazione Ticinese contro il Cancro	04-2011	04-2013	CHF 180,000	main applicant
Computational Identification Of Pathways And Genes Involved In Lymphoid Tumors: From DNA Copy Number To Expert System	"Ticino in Rete"-Computational life sciences" network	08-2010	08-2012	CHF 250,000	main applicant
Genomic Alterations And Immunogenetics Of Richter's Syndrome, A Diffuse Large B-Cell Lymphoma Subtype With Very Poor Prognosis	Oncosuisse 02296-08-2008	02-2009	02-2011	CHF 150,000	main applicant
Anaplastic Large Cell Lymphoma: One Or More Entities?	Oncosuisse 02403-02-2009	08-2009	08-2011	CHF 150,000	main applicant
Computational Identification Of Pathways And Genes Involved In Lymphoid Tumors Starting From DNA Copy Number Analysis	"Ticino in Rete" "Computational life sciences" network	08-2008	08-2010	CHF 265,000	main applicant
Identification Of Prognostic Abnormalities By Genome-Wide DNA Profiling In B-Cell Chronic Lymphocytic Leukemia	Helmut Horten Stiftung	08-2008	08-2010	CHF 200,000	main applicant
Identification Of Prognostic Abnormalities By Genome-Wide DNA Profiling In B-Cell Chronic Lymphocytic Leukemia	San Salvatore Foundation	08-2008	08-2010	CHF 342,000	main applicant
A Bayesian Approach for Integrated Cancer Genome Profiling 2	SNSF 205320-121886	08-2008	09-2010	CHF 106,120	co-applicant
Genome Wide DNA Profiling As Outcome Predictor In Diffuse Large B Cell Lymphoma	Oncosuisse 1939-8-2006	02-2007	02-2009	CHF 226,800	main applicant
Extranodal, Nodal And Splenic Marginal Zone B-Cell Lymphomas: How Much Are They Related To Each Other?	Oncosuisse 02034-02-2007	08-2007	08-2010	CHF 157,800	main applicant
Evaluation Of The Tyrosine Kinase Syk As A Possible Therapeutic Target In Lymphomas	Oncosuisse 01835-02-2006	08-2006	08-2008	CHF 177,900	main applicant

A Bayesian Approach for Integrated Cancer Genome Profiling	SNSF 205321-112430	05-2005	04-2007	CHF 92,730	co-applicant
Cancer Genes Involved In Genetic Progression Of Germinal Centre B Cell Lymphomas	Oncosuisse 01517-02-2004	08-2004	08-2006	CHF 166,900	main applicant
Primary Central Nervous System Lymphoma: From An Improved Knowledge Of Its Peculiar Molecular And Biologic Feature Towards The Optimization Of Treatment	Oncosuisse Collaborative Cancer Research 01443-12-2003	08-2004	08-2006	CHF 450,000	main applicant
Genomic profiling on mantle cell lymphoma	SAKK - Swiss Group for Clinical Cancer Research	09-2003	09-2004	CHF 70,000	main applicant

## LIST OF PUBLICATIONS

## A) ORIGINAL PAPERS

- Zadro A, Arribas AJ, Colombo MC, Cannas E, Spriano F, Cascione L, Mensah AA, Simonetta F, Petta D, Candrian, Arrigoni C\*, Bertoni F\*, Moretti M\*. A High-Throughput Bone Marrow 3D Co-Culture System to Develop Resistance to B Cell Receptor Signaling Targeted Agents in B Cell Non-Hodgkin Lymphoma. **British Journal of Haematology** 2025 January 19. <https://doi.org/10.1101/2025.01.14.632958>. (\*, co-corresponding authors).
- Koster K-L, Colombo I, Hayoz S, Eckhardt, Rojas Mora LA, Hess D, Britschgi C, Häfliger S, Imbimbo M, Bertoni F, Homicsko K, von Moos R, Sessa C, Joerger M, Stathis A. A retrospective analysis of Phase I and Phase I/II clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK). **ESMO Open** 2025: in press.
- Sala C, Iorio J, Duranti C, Montalbano A, Grandi LC, Cascione L, Raderer M, Bertoni F, Arcangeli A, Becchetti A. KV11.1 (hERG1)-centered macromolecular membrane complexes regulate proliferation in B cell lymphomas and constitute novel pharmacological targets. **Pharmacological Research** 2025, in press
- Ragaini S, Cascione L, Rinaldi A, Genuardi E, Talotta D, Almasri M, Brusca A, Zaccaria GM, Evangelista A, Civita AM, Di Rocco A, Petrucci L, Cavallo F, Celli M, Luppi M, Stelitano C, Stefani PM, Visco C, Billio A, Casaroli I, Castellino C, Pavone V, Galimberti S, Plenteda C, Merli F, Mahmoud AM, Rossi D, Gaidano G, Ladetto M, Bertoni F\*, and Ferrero S\*. The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial. **Leukemia** 2025: in press. (\*, co-senior authors).
- Sasi BK ^, Tarantelli C^, Martindale S, Civanelli E, Cannas E, Arribas AJ, Fernandes SM, Shupe SJ, Machado JH, Tyekucheva S, Ren Y, Lahn M, van der Veen L, Di Conza G, Bertoni F\*, Brown JR\*. Novel PI3K $\delta$  inhibitor roginolisib synergizes with venetoclax in hematological malignancies. **Haematologica** 2025; doi: 10.3324/haematol.2024.287180. (^, equally contributed; \*, co- corresponding authors).
- Jennings L^, Spriano F^, Reddy MM, Cascione L, Civanelli E, Rinaldi A, Bertoni F\*, and Thomas OP\*. Screening Irish marine extracts identifies new bryostatin analogue as a potent inhibitor of activated B-cell diffuse large B-cell lymphoma. **ChemBioChem** 2025: *in press*. <https://doi.org/10.1002/cbic.202500500>. (^, equally contributed; \*, co- corresponding authors).
- Patzke S, Cascione L, Melhus KB, Munz N, Arribas AJ, Gaudio E, Generalov R, Repetto-Llamazares AHV, Dahle J, Bertoni E. Comprehensive analysis of <sup>177</sup>Lu-lilotomab satetraxetan in lymphoma cell lines: implications for precision radioimmunotherapy and combination schemes. **British Journal of Haematology** 2025; 207 (5): 1855-1862.
- Munz N, J. Arribas AJ, Bordone Pittau R, Simonetta F, Stussi G, Bertoni F. Polatuzumab Vedotin and CD79B: A Study of Efficacy in R-CHOP-Resistant Diffuse Large B-Cell Lymphoma. **British Journal of Haematology** 2025: in press.
- Tarantelli C, Spriano F, Civanelli E, Aresu L, Risi G, Cannas E, Kayali O, Cascione L, Arribas AJ, Stathis A, Ko YH, Bertoni E. The anti-metabolite KAT/3BP has *in vitro* and *in vivo* anti-tumor activity in lymphoma models. **Cancers (Basel)** 2025 Jun 18;17(12):2034. doi: 10.3390/cancers17122034.
- Fiorentino F^, Spriano F^, Tomaselli D, Risi G, Fabbrizi E, Pecci V, Nanni S, Bertoni F\*, Rotili D\*, Mai A. Development of C646-based PROTAC Degradors of the Lysine Acetyltransferases CBP and p300. **ChemMedChem** 2025 Jun 17;20(12):e202400792. doi: 10.1002/cmdc.202400792. Epub 2025 Apr 11. (^, equally contributed; \*, co- corresponding authors).
- Tarantelli C, Kayali O, Civanelli E, Cascione L, Mensah AA, Folloni C, Arribas AJ, Rinaldi A, Cmiljanovic V, Mondello P\*, Bertoni F\*. Targeting of PIM kinases shows single agent efficacy and synergizes with BCL2 inhibitors in diffuse large B cell lymphoma of the ABC subtype. **Hematological Oncology** 2025 Mar;43(2):e70055. doi: 10.1002/hon.70055. (\*, co- corresponding authors).
- Hermansen J, Athanasiadis P, Yin Y, Rise A-S, Arribas A, Cascione L, Russnes H, Helland A, Mato A, Bertoni E, Tjønnfjord G, Aittokallio T, Skånland S. Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient. **Cell Death & Disease** 2025 in press
- Regazzo G^, Vari G^, Marchesi F, Díaz Méndez AB, Di Giuliani M, Sacconi A, Palombi F, Lulli V, Goeman F, Novello M, Tomassi M, Papa E, Bertoni F, Hohaus S, Mengarelli A, Rizzo MG. A predictive serum miRNA signature impacts diffuse large B cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis. **British Journal of Haematology** 2025: in press. (^, equally contributed).
- Gaudio E, Biniacka P, Arribas AJ, Cannas E, Zaman G, Unutmaz D, Bertoni F, Stoicescu DF. Novel PKN1-targeting flavonoid derivatives show potent efficacy in human lymphoma models. **EJHaem** 2025 Jun 19;6(3): e70081. doi: 10.1002/jha2.70081.
- Marelli G, Morina N, Puccio S, Iovino M, Pandini M, Portale F, Carvetta M, Mishra D, Diana E, Meregalli G, Paraboschi E, Cibella J, Peano C, Basso G, De Simone G, Camisaschi C, Magrini E, Sartori G, Karimi E, Colombo P, Lazzeri M, Casale P, Morosi L, Martano G, Asselta R, Bonavita E, Matsunami H, Bertoni F, Walsh L, Lugli E, Di Mitri D. Chemosensory receptors are lipid-detecting regulators of macrophage functions in cancer. **Nature Immunology** 2025 Jul;26(7):1182-1197. doi: 10.1038/s41590-025-02191-x. Epub 2025 Jun 30.
- Fiore D, Cappelli LV, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A, Han X, Taylor A, Chiu W, Fragiasso V, Tabbò F, Zamponi N, Di Siervi N, Kayembe C, Medico G, Patel RP, Gaudio M, Machiorlatti R, Astone G, Cacciapuoti MT, Zanetti G, Pignataro C, Eric RA, Patel S, Zammarchi F, Zanettini C, Queiroz L, Nikitina A, Kudryashova O, Karelin A, Nikitin D, Tychinin D, Postovalova E, Bagaev A, Svekolkin V, Belova E, Tikhonova K, Degryse S, Xu C, Novero D, Ponzoni M, Tiacci E, Falini B, Song, JY, Khodos I, De Stanchina E, Macari G, Cafforio L, Gardini S, Piva R, Medico E, NG SY, Moskowitza A, Epstein Z, Intlekofer AM, Ahmed D, Chan WC, Martin P, Ruan J, Bertoni F, Foà R, Brody J, Weinstock DM,

- Osan J, Santambrogio L, Elemento O, Betel D, Tam W, Ruella M, Cerchiotti L, Rabadan R, Horwitz S, Inghirami G. A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities. **Cell Report Medicine** 2025 Apr 15;6(4):102029. doi: 10.1016/j.xcrm.2025.102029. Epub 2025 Mar 26.
17. Aparo A, Avesani S, Parmigiani L, Napoli S, Bertoni F, Bonnici V, Cascione L, Giugno R. EasyCircR: Detection and reconstruction of circular RNAs post-transcriptional regulatory interaction networks. **Computers in Biology and Medicine** 2025: in press. Volume 188, April 2025, 10984613; <https://doi.org/10.1016/j.compbio.2025.109846>.
  18. Hu M, Yu K, Wang C, Liu W, Hu A, Kuang Y, Gajndran B, Zacksenhaus E, Sartori G, Bertoni F, Xiao X<sup>\*</sup>, Ben-David Y<sup>\*</sup>. FL11 induces plaque psoriasis and its inhibition attenuates disease progression. **Journal of Inflammation Research** 2025 Mar 20; 18: 4213-4231. doi: 10.2147/JIR.S500822. eCollection 2025. (\*, co-corresponding authors).
  19. Arribas AJ<sup>^</sup>, Napoli S<sup>^</sup>, Gaudio E, Herbaux CJY, Cannas E, Tarantelli C, Pittau Bordone R, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F. PI3K $\delta$  activation, IL6 over-expression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas. **Blood Advances** 2024 Dec 24;8(24):6268-6281. (^, equally contributed).
  20. Spriano F<sup>^</sup>, Sartori G, Sgrignani J, Barnabei L, Arribas AJ, Guala M, Carrasco Del Amor AM, Tomasso MR, Tarantelli C, Cascione L, Golino G, Riveiro ME, Bortolozzi R, Lupia A, Paduano F, Huguet S, Rezai K, Rinaldi A, Margheriti F, Ventura P, Guarda G, Costa G, Rocca R, Furlan A, Verdonk LM, Innocenti P, Martin NI, Viola G, Driessen C, Zucca E, Stathis A, Gahtory D, van den Nieuwboer M, Bornhauser B, Alcaro S, Trapasso F, Cristobal S, Padrick SB, Pazzi N, Cavalli F, Cavalli A, Eugenio Gaudio E<sup>^\*</sup>, Bertoni F<sup>\*</sup>. A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers. **Haematologica** 2024: 2024: Nov 1;109(11):3602-3614. (^, equally contributed; \*, co- corresponding authors).
  21. Tarantelli C<sup>^\*</sup>, Wald D<sup>^</sup>, Munz N, Spriano F, Brusca A, Cannas E, Cascione L, Gaudio E, J. Arribas AJ, Manjappa S, Golino G, Scalise L, Cacciapuoti MT, Zucca E, Stathis A, Inghirami G, van Berkel PH, Rossi D, Caimi PF, Zammarchi F, Bertoni F<sup>\*</sup>. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy. **Haematologica** 2024 Oct 1;109(10):3314-3326 (^, equally contributed; \*, co- corresponding authors).
  22. Arribas AJ<sup>^</sup>, Napoli S<sup>^</sup>, Cascione L, Bernabei L, Sartori G, Cannas E, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, Castro de Moura M, Jovic S, Bordone Pittau R, Stathis A, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, Bertoni F. ERBB4-mediated signaling is a mediator of resistance to PI3K and BTK inhibitors in B cell lymphoid neoplasms. **Molecular Cancer Therapeutics** 2024 Mar 4;23(3):368-380. doi: 10.1158/1535-7163.MCT-23-0068. Online ahead of print. (^, equally contributed).
  23. Spriano F, Tarantelli C, Cascione L, Gaudio E, Golino G, Scalise L, Cacciapuoti MT, Zucca E, Stathis A, Van Berkel PH, Inghirami G, Zammarchi F, Bertoni F. Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents. **British Journal of Haematology** 2024 Nov;205(5):1873-1882.
  24. Stathis A<sup>^</sup>, Piroso MC<sup>^</sup>, Orsucci L, Feugier P, Tani M, Ghesquière H, Musuraca G, Rossi FG, Merli F, Guièze R, Gyan E, Gini G, Marino D, Gressin R, Morschhauser F, Cavallo F, Palombi F, Conconi A, Tessoulin B, Tilly H, Zanni M, Cabras MG, Capochiani E, Califano C, Celli M, Pulsoni A, Angrilli F, Occhini U, Casasnovas RO, Cartron G, Liliana Devizzi L, Haioun C, Anna Marina Liberati AM, Houot R, Merli M, Pietrantuono G, Re F, Spina M, Landi F, Cavalli F, Bertoni F, Rossi D, Ielmini N, Borgo E, Luminari S<sup>\*</sup>, Zucca E<sup>\*</sup>, Thieblemont C<sup>\*</sup>. IELSG38: Phase 2 trial of frontline chlorambucil plus subcutaneous rituximab induction and maintenance in MALT lymphoma. **Haematologica** 2024 Aug 1;109(8):2564-2573. (^, equally contributed; \*, co- corresponding authors).
  25. Sartori G<sup>^</sup>, Tarantelli T<sup>^</sup>, Spriano F, Gaudio E, Cascione L, Mascia M, Barreca M, Arribas AJ, Licenziato L, Golino G, Ferragamo A, Pileri S, Damia G, Zucca E, Stathis A, Politz O, Wengner AM, Bertoni F. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib. **British Journal of Haematology** 2024 Jan;204(1):191-205. (^, equally contributed).
  26. Garaudé S<sup>^</sup>, Marone R<sup>^</sup>, Lepore R, Devaux A, Beerlage A, Seyres D, Dell' Aglio A, Juskevicius D, Zuin J, Burgold T, Wang S, Katta V, Manquen G, Li Y, Larrue C, Camus A, Durzynska I, Wellinger LC, Kirby I, Van Berkel PH, Kun CZ, Tamburini J, Bertoni F, Widmer CC, Tsai SQ, Simonetta F, Urlinger S, Jeker LT. Selective haematological cancer eradication with preserved haematopoiesis. **Nature** 2024 Jun;630(8017):728-735. (^, equally contributed).
  27. Zammarchi F, Havenith K, Sachini N, Janghra N, Chivers S, Idusogie E, Gaudio E, Tarantelli C, Bertelli F, Santos K, Tyrer P, Corbett S, Spriano F, Golino G, Cascione L, Bertoni F, Hartley JA, H. van Berkel PH. ADCT-602, a novel PBD dimer-containing antibody-drug conjugate for treating CD22-positive hematological malignancies. **Molecular Cancer Therapeutics**. 2024 Apr 2;23(4):520-531. Online ahead of print.
  28. Fanelli A, Licenziato L, Mazzone E, Divari S, Rinaldi A, Marino M, Maga I, Bertoni F, Marconato L<sup>\*</sup>, Aresu L<sup>\*</sup>. The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classifications. **Scientific Reports** 2024 Aug 12;14(1):18687. doi: 10.1038/s41598-024-69716-6. (\*, co-corresponding authors).
  29. Chung EYL<sup>^</sup>, Sartori G<sup>^</sup>, Ponzoni M, Cascione L, Priebe V, Zijun Y. Xu-Monette ZY, Fang X, Zhang M, Visco C, Tzankov A, Rinaldi A, Sgrignani J, Zucca E, Rossi D, Cavalli A, Inghirami G, David W, Scott DW, Ken H, Young KH, Bertoni F. ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumor cells. **British Journal of Haematology** 2023 Oct;203(2):244-254. doi: 10.1111/bjh.19018. (^, equally contributed).
  30. Johnson Z<sup>^</sup>, Tarantelli C<sup>^</sup>, Civanelli E, Cascione L, Spriano F, Fraser A, Shah P, Nomanbhoy T, Napoli S, Rinaldi A, Niewola-Staszewska K, Lahn M, Perrin D, Wenes M, Migliorini D, Bertoni F<sup>\*</sup>, van der Veen L<sup>\*</sup>, Di Conza G<sup>\*</sup>. IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that directly targets solid tumors and breaks immune tolerance. **Cancer Research Communications** 2023 Apr 14;3(4):576-591. doi: 10.1158/2767-9764.CRC-22-0477. (^, equally contributed; \*, co-corresponding authors).
  31. Spriano F, Aresu L, Cascione L, Risi G, Arribas AJ, Napoli S, Forster-Gross N, Bachmann F, Engelhardt M, Lane H, Bertoni F. The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models. **American Journal of Cancer Research** 2023 May 15;13(5):2076-2086. eCollection 2023.
  32. Guidetti F, Arribas AJ, Sartori G, Spriano F, Barnabei L, Tarantelli C, von Roemeling R, Martinez E, Zucca E, Bertoni F. Targeting IRAK4 with emavusertib in lymphoma models with secondary resistance to PI3K and BTK inhibitors. **Journal of Clinical Medicine** 2023 Jan 4;12(2):399. doi: 10.3390/jcm12020399.
  33. Barreca M, Spanò V, Rocca R, Bivacqua R, Gualtieri G, Raimondi MV, Gaudio E, Bortolozzi R, Manfreda L, Bai R, Montalbano A, Alcaro S, Hamel E, Bertoni F, Viola G, Barraja P. Identification of pyrrolo[3',4':3,4]cyclohepta[1,2-d][1,2]oxazoles as

- promising new candidates for the treatment of lymphomas. **European Journal of Medicinal Chemistry** 2023 Jun 5;254:115372. doi: 10.1016/j.ejmech.2023.115372. Epub 2023 Apr 12.
34. Robin P<sup>^</sup>, Barnabei L<sup>^</sup>, Marocco S<sup>^</sup>, Pagnoncelli J, Nicolis D, Tarantelli C, Tavilla AC, Robortella R, Cascione L, Mayoraz L, Céline M. A. Journot CMA, Mensi M, **Bertoni F\***, Stefanini I\*, Gerber-Lemaire S\*. A DNA biosensors-based microfluidic platform for attomolar real-time detection of unamplified SARS-CoV-2 virus. **Biosensors and Bioelectronics: X** 2023 May;13:100302. doi: 10.1016/j.biosx.2022.100302. Epub 2022 Dec 27. (^, equally contributed; \*, co-corresponding authors).
  35. Khameneh HJ<sup>^</sup>, Fonta N<sup>^</sup>, Zenobi A, Niogret C, Ventura P, Guerra C, Kwee I, Rinaldi A, Pecoraro M, Geiger R, Cavalli A, **Bertoni F**, Vivier E, Trumpp A and Guarda G. Myc controls IL-15-driven expansion and translational machinery of NK cells. **Life Science Alliance** 2023 Apr 27;6(7):e202302069. doi: 10.26508/lsa.202302069. Print 2023 Jul. (^, equally contributed).
  36. Licenziato L, Minoli L, Ala U, Marconato L, Fanelli A, Giannuzzi D, De Maria R, Iussich S, Orlando G, **Bertoni F**, Aresu L. Predicting outcome in dogs with diffuse large B-cell lymphoma with a novel immune landscape signature. **Veterinary Pathology** 2023 May;60(3):308-315. doi: 10.1177/03009858231162209. Epub 2023 Mar 23.
  37. Spriano F, Tarantelli C, Arribas AJ, Gaudio E, Cascione L, Aresu L, Rinaldi A, Zucca E, Rossi D, Stathis A, Murone M, Radtke F, Lehal, **Bertoni F**. *In vitro* anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103. **British Journal of Haematology** 2023 Mar;200(5):669-672. doi: 10.1111/bjh.18576. Epub 2022 Dec 9.
  38. De Pascale M, Bissegger L, Tarantelli C, Florent Beaufils F, Prescimone A, Seid Hedad HM, Kayali O, Orbegozo C, Raguž L, Schaefer T, Hebeisen P, **Bertoni F**, Wymann MP\*, Borsari C\*. Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor. **European Journal of Medicinal Chemistry** 2023 Feb 15;248:115038. doi: 10.1016/j.ejmech.2022.115038. Epub 2022 Dec 28. (\*, co-corresponding authors).
  39. Sebastiani J, Puxeddu M, Nalli M, Bai R, Altieri L, Rovella P, Gaudio E, Trisciuglio D, Spriano F, Lavia P, Fionda C, Masci D, Urbani A, Bigogno C, Dondio G, Hamel E, **Bertoni F**, Silvestri R, La Regina G. RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor *in vivo*. **European Journal of Medicinal Chemistry** 2023 Jan 15;246:114997. doi: 10.1016/j.ejmech.2022.114997. Epub 2022 Dec 5.
  40. Barreca M, Spanò V, Rocca R, Bivacqua R, Abel AC, Maruca A, Montalbano A, Raimondi MV, Tarantelli C, Gaudio E, Cascione L, Rinaldi A, Bai R, Steinmetz M, Prota A, Alcaro S, Hamel E, **Bertoni F\***, Barraja P\*. Development of [1,2]oxazoloisindoles tubulin polymerization inhibitors: further chemical modifications and potential therapeutic effects against lymphomas. **European Journal of Medicinal Chemistry** 2022 Dec 5;243:114744. doi:10.1016/j.ejmech.2022.114744. Epub 2022 Sep 8. (\*, co-corresponding authors).
  41. Arribas AJ<sup>^\*</sup>, Napoli S<sup>^</sup>, Cascione L, Sartori G, Barnabei L, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, de Moura MC, Jovic S, Bordone Pittau R, Di Veroli A, Stathis A, Cruciani G, Stussi G, Gattei V, Brown JR, Esteller M, Zucca E, Rossi D, **Bertoni F\***. Resistance to PI3K $\delta$  inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. **Haematologica** 2022 Nov 1;107(11):2685-2697. doi: 10.3324/haematol.2021.279957. (^, equally contributed; \*, co-corresponding authors).
  42. Giannuzzi D, Marconato L, Fanelli A, Licenziato L, De Maria R, Rinaldi A, Rotta L, Rouquet N, Birolo G, Fariselli P, Mensah AA, **Bertoni F\***, Aresu L\*. The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications. **Lab Animal (NY)**. 2022 Jul;51(7):191-202. (\*, co-corresponding authors).
  43. Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, Cacciaputi MT, Mensah AA, Sartori G, Munz N, Forcato M, Biccato S, Chiappella A, Ghione P, Elemento O, Cerchietti L, Inghirami G, **Bertoni F**. Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. **Haematologica** 2022 May 1;107(5):1131-1143.
  44. Rizzello C, Cancila V, Sangaletti S, Botti L, Rratti C, Milani M, Dugo M, **Bertoni F**, Tripodo C, Chiodoni C, Colombo MP. Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling. **Molecular Cancer** 2022 Dec 12;21(1):215. doi: 10.1186/s12943-022-01687-6.
  45. Terzi di Bergamo L, Guidetti F, Rossi F, **Bertoni F**, Cascione L. HTGQC and shinyHTGQC: an R package and shinyR application for quality controls of HTG EDGE-seq protocols. **Gigabyte**, 2022 Dec 2;2022:gigabyte74. doi: 10.46471/gigabyte.74. eCollection 2022.
  46. Virgilio T, Bordini J, Cascione L, Sartori G, Latino I, Molina-Romero D, Leoni C, Akhmedov M, Rinaldi A, Arribas AJ, Morone D, Seyed Jafari SM, Bersudsky M, Ottolenghi A, Kwee I, Chiaravalli AM, Sessa F, Hunger RE, Bruno A, Mortara L, Voronov E, Monticelli S, Apte RN, **Bertoni F**, Gonzalez SF. Subcapsular sinus macrophages promote melanoma metastasis in the sentinel lymph nodes by releasing IL-1 $\alpha$ , which upregulates STAT3 signaling in the tumor. **Cancer Immunology Research** 2022 Dec 2;10(12):1525-1541. doi: 10.1158/2326-6066.CIR-22-0225.
  47. Spriano F<sup>^\*</sup>, Sartori G<sup>^</sup>, Tarantelli C, Barreca M, Golino G, Rinaldi A, Napoli S, Mascia M, Scalise L, Arribas AJ, Cascione L, Zucca E, Stathis A, Gaudio E, **Bertoni F\***. Pharmacologic screening identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma. **EJHaem** 2022 Jul 27;3(3):764-774 (^, equally contributed; \*, co-corresponding authors).
  48. Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, Fernandes SM, Arribas AJ, Hilli AK, Taskén K, **Bertoni F**, Mato AR, Normant E, Brown JR, Tjønnfjord GE, Aittokallio T, Skånland S. Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia. **Clinical Cancer Research** 2022 Oct 14;28(20):4444-4455.
  49. Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi, Dirnhofer S, Ceriani L, Sartori G, **Bertoni F**, Buske C, Zucca E\*, Hiddemann H\*. SAKK 35/15: A phase I trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. **Blood Advances** 2022 Jul 27;6(13):3911-3920. (\*, co-corresponding authors).
  50. Chilà R, Guffanti F, Chiappa M, Panini N, Conconi D, Rinaldi A, Cascione L, **Bertoni F**, Fratelli M, Damia G. Stable CDK12 knock-out ovarian cancer cells do not show increased sensitivity to cisplatin and PARP inhibitor treatment. **Frontiers in Oncology, section Pharmacology of Anti-Cancer Drugs** 2022 Jul 13;12:903536.
  51. Bonfiglio F<sup>^</sup>, Brusca G<sup>^</sup>, Guidetti F<sup>^</sup>, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MC, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Buehler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Francesco Piazza F, Pizzolitto S, Rambaldi A, Sabatini E, Salles G, Santambrogio E, Scarfò L, Stathis A, Stüssi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Zaja F, Zenz T, Zinzani PL, Khiabani H, Calcinotto A, Bertoni F, Bhagat G, Campo E, De Leval L,

- Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. **Blood** 2022; Feb 3;139(5):732-747. doi: 10.1182/blood.2021012386. (^, equally contributed; \*, co-corresponding authors).
52. Piroso MC, Zhang L, Hitz F, Novak U, Hess D, Terrot T, Pascale M, Mazzucchelli L, Bertoni F, Cavalli F, Zucca E, Stathis A. A phase I trial of Inotuzumab Ozogamicin in combination with Temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. **Leukemia and Lymphoma** 2022, 63 (1): 117-123 doi: 10.1080/10428194.2021.1966780.
53. Argnani L, Casadei B, Pelusi C, Lo Preiato V, Pagotto U, Bertoni F, Zinzani PL. Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors. **Scientific Reports** 2022 Feb 2;12(1):1753.
54. Frazzari R, Cusenza VY, Pistoni M, Canovi L, Cascione L, Bertoni F, and Merli F. KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1-silencing and hypomethylating drugs in lymphoma cells. **Oncology Reports** 2022 Jan;47(1):10.
55. Sartori G, Napoli S, Cascione L, Chung EYL, Priebe V, Arribas AJ, Mensah AA, Dall'Angelo M, Falzarano C, Barnabei L, Forcato M, Rinaldi A, Bicciato S, Thome M, Bertoni F. ASB2 is a direct target of FLI1 that sustains NF- $\kappa$ B pathway activation in germinal center-derived diffuse large B-cell lymphoma. **Journal of Experimental & Clinical Cancer Research** 2021 Nov 11;40(1):357. doi: 10.1186/s13046-021-02159-3.
56. Tarantelli C, Cannas E, Ekeh H, Moscatello C, Gaudio E, Cascione L, Napoli S, Cesare Rech C, Testa A, Maniaci C, Rinaldi A, Zucca E, Stathis A, Ciulli A, Bertoni F. The BET degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. **Exploration of Targeted Anti-tumor Therapy** 2021; 2: 586-601.
57. Mensah AA, Spriano F, Sartori G, Priebe V, Cascione L, Gaudio E, Tarantelli C, Civanelli E, Aresu L, Rinaldi A, Damia G, Lovati E, Zucca E, Stathis A, Pietra C, Bertoni F. Study of the anti-lymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. **Blood Advances** 2021, 5 (10): 2467-2480.
58. Munz N, Cascione L, Parmigiani L, Tarantelli C, Rinaldi A, Cmiljanovic N, Cmiljanovic V, Giugno R, Bertoni F, Napoli S. Exon-intron differential analysis reveals the role of competing endogenous RNAs in regulation of translation by post transcriptional mechanism. **Non-Coding RNA** 2021, 7(2), 26. <https://doi.org/10.3390/ncrna7020026>
59. Rinaldi F<sup>^</sup>, Marchesi F<sup>^</sup>, Palombi F, Pelosi A, Di Pace AL, Annibaldi O, Tomarchio V, Marino M, Cantonetti M, Vaccarini S, Papa E, Moretta L, Bertoni F, Mengarelli A, Regazzo G<sup>\*</sup>, Rizzo MG<sup>\*</sup>. miR-22 a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients. **British Journal of Haematology** 2021 Nov;195(3):399-404 (^, equally contributed)(\*, co-corresponding authors).
60. La Ferlita A<sup>^</sup>, Alaimo S<sup>^</sup>, Di Bella S, Martorana E, Laliotis GI, Bertoni F, Cascione L, Tschlis PN, Ferro A, Bosotti R, Pulvirenti A. RNA detector: a free user-friendly and stand-alone software for RNA-Seq data analysis. **BMC Bioinformatics** 2021 Jun 3;22(1):298. doi: 10.1186/s12859-021-04211-7. (^, equally contributed).
61. Rango E<sup>^</sup>, Di Maria S<sup>^</sup>, Zamperini C, Poggialini F, Crespan E, Perini C, Sabetta S, Saponara S, Fusi F, Maga G, Angelucci A, Gaudio E, Bertoni F, Schenone S, Botta L<sup>\*</sup>, Dreassi E<sup>\*</sup>, Botta M. Tyrosine kinase inhibitor Si409 has in vitro and in vivo anti-tumor activity against diffuse large B-cell lymphoma. **Pharmaceutical Chemistry Journal** 2023; 56, 1616-1626. (^, equally contributed; \*, co-corresponding authors).
62. De Martino M, Nicolau-Neto P, Ribeiro Pinto LF, Traverse-Glehen A, Bachy E, Gigantino V, De Cecio R, Bertoni F, Chieffi P, Fusco A, Esposito F. HMGA1 induces EZH2 overexpression in human B-cell lymphomas. **American Journal of Cancer Research** 2021 May 15;11(5):2174-2187.
63. Pietrobono S, Gaudio E, Gagliardi S, Zitani M, Carrassa L, Migliorini F, Petricci E, Manetti F, Makukhin N, Bond AG, Paradise BD5, Ciulli A, Fernandez-Zapico ME, Bertoni F, Stecca B. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma. **Oncogene** 2021 Jun;40(22):3799-3814.
64. Bernasocchi T, El Tekle G, Bolis M, Mutti A, Vallerga A, Brandt L, Spriano F, Svinkina T, Zoma M, Ceserani V, Rinaldi A, Hana Janouskova H, Bossi D, Cavalli M, Mosole S, Geiger R, Dong Z, Yang CG, Albino D, Rinaldi A, Schraml P, Linder S, Carbone G, Alimonti A, Bertoni F, Moch H, Carr S, Zwart W, Kruithof-de Julio M, Rubin M, Udeshi N, Theurillat JP. Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer. **Nature Communications** 2021 Feb 2;12(1):734.
65. Montalbano A, Sala C, Abrardo C, Murciano N, Jahanfar F, D'Amico M, Bertoni F, Becchetti A, Arcangeli A. Data describing the effects of potassium channels modulators on outward currents measured in human lymphoma cell lines. **Data in Brief** 2021; 34 (2). 106668.
66. Aresu L, Agnoli C, Nicoletti A, Fanelli A, Martini V, Bertoni F, Marconato L. Phenotypical characterization and clinical outcome of canine Burkitt-like lymphoma. **Frontiers in Veterinary Science** 2021 Mar 17;8:647009. doi: 10.3389/fvets.2021.647009.
67. Spriano F, Gaudio E, Cascione L, Tarantelli C, Melle F, Motta G, Priebe V, Rinaldi A, Golino G, Mensah AA, Aresu L, Zucca E, Pileri S, Witcher M, Brown B, Wahlestedt C, Giles F, Stathis A, Bertoni F. Anti-tumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. **Blood Advances** 2020; 4(17): 4124-4135.
68. Tarantelli T<sup>^</sup>, Lange M<sup>^</sup>, Gaudio E, Cascione L, Spriano F, Kwee I, Arribas AJ, Rinaldi A, Jourdan T, Berthold M, Sturz A, Sperl C, Margheriti F, Scalise L, Gritti G, Rossi D, Stathis A, Liu N, Zucca E, Politz O, Bertoni F. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. **Blood Advances** 2020, 4: 819-829. (^, equally contributed).
69. Gaudio E<sup>^</sup>, Tarantelli C<sup>^</sup>, Spriano F, Guidetti F, Sartori G, Bordone R, Arribas JA, Cascione L, Bigioni M, Merlino G, Fiascarelli A, Bressan A, Mensah AA, Golino G, Lucchini R, Bernasconi E, Rossi D, Zucca E, Stussi A, Stathis A, Boyd RS, Dusek RL, Bisht A, Attanasio N, Rohlf C, Pellacani A, Binaschi M, Bertoni F. Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. **Haematologica** 2020; 105(11):2584-2591. doi: 10.3324/haematol.2019.227215. (^, equally contributed).
70. Ferrero S<sup>^</sup>, Rossi D<sup>^</sup>, Rinaldi A<sup>^</sup>, Brusca G, Spina V, Eskelund CW, Evangelista A, Moia R, Kwee I, Dahl C, Di Rocco A, Stefoni V, Diop F, Favini C, Ghione P, Mahmoud AM, Schipani M, Kolstad A, Barbero D, Novero D, Paulli M, Zamò A, Jerkeman M, Gomes da Silva M, Santoro A, Molinari A, Ferreri A, Grønbaek K, Piccin A, Cortelazzo S, Bertoni F<sup>\*</sup>, Ladetto M<sup>\*</sup>, Gaidano G<sup>\*</sup>. *KMT2D* mutations and *TP53* disruptions are poor prognostic biomarkers in MCL receiving high-dose therapy: a FIL study. **Haematologica** 2020 Jun;105(6):1604-1612. (^, equally contributed)(\*, co-corresponding authors).
71. Priebe V<sup>^</sup>, Sartori G<sup>^</sup>, Napoli S, Chung EYL, Cascione L, Kwee I, Arribas AJ, Mensah AA, Rinaldi A, Ponzoni M, Zucca E, Rossi D, Efremov D, Lenz G, Thome M, Bertoni F. Role of ETS1 in the transcriptional network of diffuse large B cell lymphoma of the activated B cell-like type. **Cancers** 2020 Jul 15;12(7):1912. (^, equally contributed).

72. Laginestra MA<sup>^</sup>, Cascione L<sup>^</sup>, Motta G, Fuligni F, Agostinelli C, Rossi M, Sapienza MR<sup>1</sup>, Righi S, Broccoli A, Indio V, Melle F, Tabanelli V, Calleri A, Novero D, Facchetti F, Inghirami G, Sabattini E, Bertoni F<sup>\*</sup>, Pileri SA<sup>\*</sup>. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. **Modern Pathology** 2020 Feb;33(2):179-187. doi: 10.1038/s41379-019-0279-8 (<sup>^</sup>, equally contributed)(<sup>\*</sup>, co-corresponding authors).
73. Spanò V<sup>^</sup>, Rocca R<sup>^</sup>, Barreca M<sup>^</sup>, Giallombardo D, Carbone A, Raimondi MV, Gaudio E, Bortolozzi R, Bai R, Tassone P, Montalbano A, Alcaro S, Hamel E, Viola G, Bertoni F, Barraja P. Pyrrolo [2',3':3,4]cyclohepta [1,2-d][1,2]oxazoles, a new class of antimetabolic agents, active against multiple malignant cell types. **Journal of Medicinal Chemistry** 2020 Oct 22; 63(20): 12023-12042 (<sup>^</sup>, equally contributed).
74. Mondello P, Cuzzocrea S, Arrigo C, Pitini V, Mian M<sup>\*</sup>, Bertoni F<sup>\*</sup>. STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in Primary Central Nervous System Lymphoma. **Hematological Oncology** 2020 Feb;38(1):106-110. doi: 10.1002/hon.2679. (<sup>\*</sup>, co-corresponding authors).
75. Ricci D, Guffanti F, Affatato R, Brunelli L, Pastorelli R, Fruscio R, Perego P, Bani MR, Chiorino G, Rinaldi A, Bertoni F, Fratelli M, Damia G. Establishment of patient-derived tumor Xenograft models of mucinous ovarian cancer. **American Journal of Cancer Research** 2020 Feb 1;10(2):572-580.
76. Unzue A, Jessen-Trefzer C, Spiliotopoulos D, Gaudio E, Tarantelli C, Dong J, Zhao H, Liebl J, Zahler S, Bernasconi E, Sartori G, Cascione L, Bertoni F<sup>\*</sup>, Śledź P, Caffisch A<sup>\*</sup> and Nevado C<sup>\*</sup>. Understanding the Mechanism of Action of Pyrrolo[3,2-b]quinoxaline-derivatives as kinase Inhibitors. **RSC Medicinal Chemistry** 2020,11, 665-675 (<sup>\*</sup>, co-corresponding authors).
77. De Martino M, De Biase D, Forzati F, Credendino SC, Palma G, Barbieri A, Arra C, Paciello O, Gaudio E, Ponzoni M, Chieffi P, Bertoni F, Fusco A<sup>\*</sup> and Esposito F<sup>\*</sup>. *HMGAI1-pseudogene7* transgenic mice develop B cell lymphomas. **Scientific Reports** 2020 Apr 27;10(1):7057. doi: 10.1038/s41598-020-62974-0. (<sup>\*</sup>, co-corresponding authors).
78. Spriano F<sup>^</sup>, Chung EYL<sup>^</sup>, Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V, Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, Testoni M, Genini D, Ye BH, Zucca E, Stathis A, Lannutti B, Toretzky JA, Bertoni F. The ETS inhibitors YK-4-279 and TK-216 are novel anti-lymphoma agents. **Clinical Cancer Research** 2019 Aug 15;25(16):5167-5176. doi: 10.1158/1078-0432.CCR-18-2718. (<sup>^</sup>, equally contributed).
79. Hicks SW<sup>^</sup>, Tarantelli C<sup>^</sup>, Wilhem A, Gaudio E, Li M, Arribas AJ, Spriano F, Pittau Bordone R, Cascione L, Lai KC, Qiu Q, Taborelli M, Rossi D, Stussi G, Zucca E, Stathis A, Sloss CM<sup>\*</sup>, Bertoni F<sup>\*</sup>. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models. **Haematologica** 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. [Epub ahead of print]. (<sup>^</sup>, equally contributed; <sup>\*</sup>, co-senior authors).
80. Ferrero S<sup>^</sup>, Rossi D<sup>^</sup>, Rinaldi A<sup>^</sup>, Bruscazzin A, Spina V, Eskelund CW, Evangelista A, Moia R, Kwee I, Dahl C, Di Rocco A, Stefoni V, Diop F, Favin C, Ghione P, Mahmoud AM, Schipani M, Kolstad A, Barbero D, Novero D, Paulli M, Zamò A, Jerkeman M, Gomes da Silva M, Santoro A, Molinari A, Ferreri A, Grønbaek K, Piccin A, Cortelazzo S, Bertoni F<sup>\*</sup>, Ladetto M<sup>\*</sup>, Gaidano G<sup>\*</sup>. *KMT2D* mutations and *TP53* disruptions are poor prognostic biomarkers in MCL receiving high-dose therapy: a FIL study. **Haematologica** 2019 Sep 19. pii: haematol.2018.214056. doi: 10.3324/haematol.2018.214056. [Epub ahead of print]. (<sup>^</sup>, equally contributed)(<sup>\*</sup>, co-senior authors).
81. Giannuzzi D, Giudice L, Marconato L, Ferraresso S, Giugno R, Bertoni F, Aresu L. Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog. **Veterinary and Comparative Oncology** 2020 Mar 10. doi: 10.1111/vco.12588.
82. Spriano F<sup>^</sup>, Tarantelli C<sup>^</sup>, Gaudio E, Gerlach MM, Priebe V, Cascione L, Bernasconi E, Targa A, Mascia M, Dirnhofer S, Stathis A, Zucca E, Bertoni F. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. **British Journal of Haematology** 2019 Dec;187(5):595-601 (<sup>^</sup>, equally contributed).
83. Tarantelli C, Gaudio E, Hillmann P, Spriano F, Sartori G, Aresu L, Cascione L, Rageot D, Kwee I, Beauflis F, Zucca E, Stathis A, Wymann MP, Cmiljanovic V, Fabbro D, Bertoni F. The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as single agent and in combination of venetoclax. **Cancers (Basel)** 2019 Jun 4;11(6). pii: E775. doi: 10.3390/cancers11060775.
84. Arribas AJ<sup>^</sup>, Rinaldi A<sup>^</sup>, Chiodin G, Kwee I, Mensah AA, Cascione L, Rossi D, Kanduri M, Rosenquist R, Zucca E, Johnson PW, Gaidano G, Oakes CO, Bertoni F<sup>\*</sup>, Forconi F<sup>\*</sup>. Genome-wide promoter methylation of hairy cell leukemia. **Blood Advances** 2019 Feb 12;3(3):384-396. doi: 10.1182/bloodadvances.2018024059. (<sup>^</sup>, equally contributed; <sup>\*</sup>, co-senior authors).
85. Tarantelli C, Zhang L, Curti E, Gaudio E, Spriano F, Priebe V, Cascione L, Arribas AJ, Zucca E, Rossi D, Stathis A, Bertoni F. The BTK inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. **Haematologica** 2019 Jul; 104(7): e307–e309.
86. Cascione L<sup>^</sup>, Rinaldi A<sup>^</sup>, Bruscazzin A, Tarantelli C, Arribas A, Kwee I, Pecciarini L, Mensah AA, Spina V, Chung EYL, Terzi di Bergamo L, Dirnhofer S, Tzankov A, Miranda R, Young KH, Traverse-Glehen A, Gaidano G, Swerdlow S, Gascoyne RD, Rabadan R, Ponzoni M, Bhagat G, Rossi D, Zucca E, Bertoni F. Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. **Haematologica** 2019 Dec;104(12):e558-e561. doi: 10.3324/haematol.2018.214957. [Epub ahead of print]. (<sup>^</sup>, equally contributed).
87. Aresu L<sup>\*</sup>, Ferraresso S, Marconato L, Cascione L, Napoli S, Gaudio E, Kwee I, Tarantelli C, Testa A, Maniaci C, Ciulli A, Hillmann P, Bohnacker T, Wymann MP, Comazzi S, Milan M, Riondato F, Dalla Rovere G, Giannuzzi D, Bertoni F<sup>\*</sup>. New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease. **Haematologica** 2019 Jun;104(6):e256-e259. doi: 10.3324/haematol.2018.207027. [Epub ahead of print] (<sup>\*</sup>, co-senior authors).
88. Astorgues-Xerri L<sup>^</sup>, Vázquez R<sup>^</sup>, Odore E, Rezai K, Kahatt C, MacKenzie S, Bekradda M, Coudé MM, Dombret H, Gardin C, Lokiec F, Raymond E, Noel K, Cvitkovic E, Herait P, Bertoni F<sup>\*</sup>, Riveiro ME<sup>\*</sup>. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models. **Leukemia and Lymphoma** 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1617860 (<sup>^</sup>, equally contributed; <sup>\*</sup>, co-senior authors).
89. Cascione L<sup>^</sup>, Giudice L<sup>^</sup>, Ferraresso S, Marconato L, Giannuzzi D, Napoli S, Bertoni F<sup>\*</sup>, Giugno R<sup>\*</sup>, Aresu L<sup>\*</sup>. Long non-coding RNAs as molecular signature to canine B-cell lymphoma characterization. **Non-Coding RNA** 2019 Sep 19;5(3). pii: E47. doi: 10.3390/ncrna5030047 (<sup>^</sup>, equally contributed; <sup>\*</sup>, co-senior authors).
90. Rødland GE, Melhus K, Generalov R, Gilani S, Bertoni F, Dahle J, Syljuåsen RG, Patzke S. The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines. **Frontiers in Oncology** 2019 Nov 29;9:1301. doi: 10.3389/fonc.2019.01301
91. Tarantelli T<sup>\*</sup>, Gaudio E<sup>\*</sup>, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Bordone Pittau R, Beauflis F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V,

- Rossi D, Stathis A, Stussi G, Broggin M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F. PQR309 is a novel dual PI3K/mTOR inhibitor with pre-clinical antitumor activity in lymphomas as a single agent and in combination therapy. **Clinical Cancer Research**: 2018;24(1):120-129. (\*, equally contributed)
92. Mensah AA\*, Cascione L\*, Gaudio E, Tarantelli C, Bomben R, Bernasconi E, Zito D, Lampis A, Hahne JC, Rinaldi A, Stathis A, Zucca E, Kwee I, Gattei V, Valeri N, Riveiro ME, Bertoni F. Bromodomain and Extra-Terminal Domain Inhibition Modulates the Expression of Pathologically Relevant MicroRNAs in Diffuse Large B-Cell Lymphoma. **Haematologica** 2018; 103(12): 2049-2058. (\*, equally contributed)
  93. Tarantelli C\*, Bernasconi E\*, Gaudio E, Cascione L, Restelli V, Arribas A, Spriano F, Rinaldi A, Mensah AA, Kwee I, Ponzoni M, Zucca E, Carrassa L, Riveiro ME, Rezai K, Stathis A, Cvitkovic E, Bertoni F. The BET Bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. **ESMO Open** 2018 Sep 26;3(6):e000387 <http://dx.doi.org/10.1136/esmoopen-2018-000387>. (\*, equally contributed).
  94. Cascione L, Rinaldi A, Chiappella A, Kwee I, Ciccone G, Altenbuchinger M, Kohler C, Vitolo U, Inghirami G, Bertoni F. Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. **British Journal of Haematology** 2018 Aug;182(3):453-456. doi: 10.1111/bjh.14817.
  95. Conconi A, Zucca E, Margiotta-Casaluci G, Darling K, Hasse B, Battegay M, Staehelin C, Novak U, Schmid P, Scherrer A, Dirnhofer S, Kwee I, Nassi L, Cavalli F, Gaidano G, Bertoni F\*, Bernasconi E\* and the Swiss HIV Cohort study (SHCS). Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. **Hematological Oncology** 2018 Dec;36(5):757-764. (\*, co-corresponding authors).
  96. Bergaggio E, Riganti C, Garaffo G, Vitale N, Mereu E, Bandini C, Pellegrino E, Pullano V, Omede' PM, Todoerti K, Cascione L, Audrito V, Riccio A, Rossi A, Bertoni F, Deaglio S, Neri A, Palumbo A, Piva R. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. **Blood** 2019 Jan 10;133(2):156-167.
  97. Bonnici V, Busato F, Aldegheri S, Akhmedov M, Cascione L, Arribas Carmena A, Bertoni F, Bombieri N, Kwee I, Giugno R. cuRnet: an R package for graph traversing on GPU. **BMC Bioinformatics** 2018 Oct 15;19(Suppl 10):356. doi: 10.1186/s12859-018-2310-3.
  98. Da Ros S., Aresu L, Ferrareso S, Zorzan E, Gaudio E, Bertoni F, Dacasto M, Giantin M. Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: an *in vitro* and *in vivo* approach. **PLOS One** 2018 Dec 11;13(12):e0208709. doi: 10.1371/journal.pone.0208709. eCollection 2018.
  99. Spina S, Bruscazzin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D. Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. **Blood** 2018 May 31;131(22):2413-2425.
  100. Gerber B\*, Manzoni M\*, Spina V, Bruscazzin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. **Haematologica** 2018 Jun;103(6):e245-e248. (\*, equally contributed)
  101. Chen J, Guccini I, Mitri DD, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. **Nature Genetics** 2018 Feb;50(2):219-228.
  102. Bergmann TJ, Fregno I, Fumagalli F, Rinaldi A, Bertoni F, Boersema PJ, Picotti P, Molinari M. Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides. **The Journal of Biological Chemistry** 2018 Apr 13;293(15):5600-5612. [Epub ahead of print].
  103. Chung E \*, Spriano F \*, Panini N, Cascione L, Rinaldi A, Erba E, Stathis A, D'Incalci M, Bertoni F^, Gatta R^ . Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma. **British Journal of Haematology** 2018 Apr 2. doi: 10.1111/bjh.15212. [Epub ahead of print]. (\*, equally contributed; ^, co-corresponding authors)
  104. Restelli V\*, Vagni M\*, Arribas A, Bertoni F, Damia G & Carrassa L. Inhibition of Chk1 and Wee1 as a new therapeutic approach in diffuse large B cell lymphomas with Myc deregulation. **British Journal of Haematology** , 2018, 181, 122–151. (\*, equally contributed).
  105. Bandini C, Pupuleku A, Spaccarotella E, Pellegrino E, Wang R, Vitale N, Duval C, Cantarella D, Rinaldi A, Provero P, Di Cunto F, Medico E, Bertoni F, Inghirami G, Piva R. IRF4 mediates the oncogenic effects of STAT3 in Anaplastic Large Cell Lymphomas. **Cancers (Basel)** 2018 Jan 18;10(1). pii: E21. doi: 10.3390/cancers10010021..
  106. Restelli V, Lupi M, Vagni M, Chilà R, Bertoni F, Damia G, Carrassa L. Combining ibrutinib with Chk1 inhibitors synergistically targets mantle cell lymphoma cell lines. **Targeted Oncology** 2018 Apr;13(2):235-245.
  107. Bernasconi E \*, Gaudio E\*, Lejeune P, Tarantelli C, Cascione L, Kwee I, Spriano F, Rinaldi A, Mensah AA, Chung E, Stathis A, Siegel S, Schmees N, Ocker M, Zucca E, Haendler B, Bertoni F. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. **British Journal of Haematology** 2017; 178(6): 936-948. (\*, equally contributed)
  108. Gaudio E\*, Paduano F\*, Pinton S, D'Agostino S, Rocca R, Costa G, Ngankeu A, Aqeilan R.I., Croce C.M., Bertoni F, Alcaro S, Trapasso F. TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line. **British Journal of Haematology** 2017 Oct 19. doi: 10.1111/bjh.14989. [Epub ahead of print]: in press (\*, equally contributed)
  109. Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinikina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. **Nature Medicine** 2017; 23(9): 1046-1054.
  110. Vázquez R, Riveiro ME, Astorgues-Xerri L, Odore E, Rezai K, Erba E, Panini N, Rinaldi A, Kwee I, Beltrame L, Bekradda, Cvitkovic E, Bertoni F, Frapolli R, D'Incalci M. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. **Oncotarget** 2017; 8(5):7598-7613.
  111. Akhmedov M, Kedaigle A, Escalante Ching R, Montemmani R, Bertoni F, Fraenkel E, Kwee I. PCSF: an R-package for Network-Based Interpretation of High-throughput Data. **PLOS Computational Biology** 2017 Jul 31;13(7):e1005694.
  112. Puddinu V, Radice E, Casella S, Thelen S, Dirnhofer S, Bertoni F, Thelen M. ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration. **Oncotarget** 2017; doi.org/10.18632/oncotarget.18844
  113. Bujisic B, De Gassart A, Tallant R, Demaria O, Zaffalon L, Chelbi S, Gilliet M, Bertoni F, Martinon F. Impaired IRE1 expression and XBP1 activation is a hallmark of GCB-DLBCL and contributes to tumor growth. **Blood** 2017 Apr 27;129(17):2420-2428.

114. Leoni C, Montagner S, Rinaldi A, Bertoni F, Polletti S, Balestrieri C, Monticelli S. Dnmt3a restrains mast cell inflammatory responses. **Proceedings of the National Academy of Sciences** 2017; 114(8): E1490-E1499.
115. Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, Ponzoni M, Cascione L, Targa A, Stathis A, Goodstal S, Zucca E, & Bertoni F. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in pre-clinical models of aggressive lymphomas. **Annals of Oncology** 2016 Jun;27(6):1123-8. (\*, equally contributed).
116. Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, D'Antuono R, Pinton S, Losa M, Gnetti L, Arribas A, Fraering P, Bertoni F, Nepveu A, Alimonti A. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. **Nature Communications** 2016 Dec 12;7:13719.
117. Boi M\*, Todaro M\*, Vurchio V, Ning Yang S, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F<sup>^</sup>, Inghirami G<sup>^</sup>. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. **Oncotarget** 2016 Nov 29;7(48):79637-79653. (\*, equally contributed; <sup>^</sup>, co-corresponding authors)
118. Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D'Incalci M, Noel K, Cvitkovic E, Raymond E, & Bertoni F. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. **Oncotarget** 2016 Dec 20;7(51):84675-84687.
119. Gaudio E, Tarantelli C, Ponzoni M, Odore E, Rezai K, Bernasconi E, Cascione L, Rinaldi A, Stathis A, Riveiro E, Cvitkovic E, Zucca E, Bertoni F. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong *in vivo* antitumor activity in lymphoma. **Oncotarget** 2016 Sep 6;7(36):58142-58147.
120. Ganapathi KA, Jobanputra V, Iwamoto F, Chen J, Cascione L, Nahum O, Levy B, Xie Y, Khattar P, Hoehn D, Bertoni F, Murty VV, Pittaluga S, Jaffe ES, Alobeid B, & MM, Bhagat G. The Genetic Landscape of Dural Marginal Zone Lymphomas. **Oncotarget** 2016 Jul 12;7(28):43052-43061.
121. Spina V\*, Hossein Khiabani H\* Messina M, Monti S, Cascione L, Brusca G, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbò F, Zairis S, Diop F, Cerri M,<sup>1</sup> Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B, Inghirami G, Bertoni F, Foà R, Rabadan R, Gaidano G, Rossi D. The genetics of nodal marginal zone lymphoma. **Blood** 2016 Sep 8;128(10):1362-73. (\*, equally contributed).
122. Scarfò I\*, Pellegrino E\*, Mereu E\*, Kwee I, Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti R, Circosta P, Abate A, Barreca A, Domenico Novero D, Mathew S, Rinaldi A, Tiacci E, Serra S, Deaglio S, Neri A, Falini B, Rabadan R, Bertoni F, Inghirami G<sup>^</sup>, Piva R<sup>^</sup>, and the European T-Cell Lymphoma Study Group. Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts. **Blood**, 2016 Jan 14;127(2):221-32. (\*, equally contributed; <sup>^</sup>, co-corresponding authors)
123. Rancoita PMV, Zaffalon M, Zucca E, Bertoni F, de Campos C. Bayesian network data imputation with application to survival tree analysis. **Computational Statistics and Data Analysis**, 2016 January, 93: 373–387.
124. Arribas AJ\*, Rinaldi A\*, Mensah AA, Kwee I, Cascione L, Martinez-Climent JA, Oscier D, Arcaini L, Baldini L, Marasca R, Thieblemont C, Souliere J, Forconi F, Zamo' A, Bonifacio M, Mollejo M, Facchetti F, Dirnhofer S, Ponzoni M, Bhagat, Piris MA, Gaidano G, Zucca E, Rossi D, Bertoni F. DNA methylation-profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. **Blood** 2015 Mar 19;125(12):1922-31. (\*, equally contributed)
125. Boi M\*, Gaudio E\*, Bonetti P\*, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F. The BET Bromodomain inhibitor OTX015 affects pathogenetic pathways in pre-clinical B-cell tumor models and synergizes with targeted drugs. **Clinical Cancer Research**, 2015 Apr 1;21(7):1628-38. (\*, equally contributed)
126. Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Barreca A, Novero D, Gaudio M, Aliberti S, Di Giacomo F, Tousseyn T, Lasorsa E, Crescenzo R, Bessone L, Ficarra E, Acquaviva A, Rinaldi A, Ponzoni M, Longo DL, Aime S, Cheng M, Ruggeri B, Piccaluga PP, Pileri S, Tiacci E, Falini B, Pera-Gresely B, Cerchietti L, Iqbal I, Chan WC, Shultz L, Kwee I, Piva R, Wlodarska I, Rabadan R\*, Bertoni F\*, Inghirami G\* (\*, co-corresponding authors). A novel Patient Derived Tumorgraft model with TRAF1-ALK Anaplastic Large Cell Lymphoma translocation. **Leukemia** 2015 Jun;29(6):1390-401
127. Bernasconi E, Gaudio E, Kwee I, Rinaldi A, Cascione L, Tarantelli C, Mensah AA, Stathis A, Zucca E, Vesci L, Giannini G, Bertoni F. The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models. **British Journal of Haematology** 2015;171(3):378-86.
128. Mensah AA, Kwee I, Gaudio E, Rinaldi A, Ponzoni M, Cascione E, Fossati G, Stathis A, Zucca E, Caprini G, Bertoni F. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of *CDKN1A* expression levels in mediating their anti-tumor response. **Oncotarget** 2015 Mar 10;6(7): 5059-71.
129. Vesci L\*, Bernasconi E\*, Milazzo FM, De Santis R, Gaudio E, Kwee I, Rinaldi A, Pace S, Carollo V, Giannini G, Bertoni F. Preclinical antitumor activity of ST7612AA1: a novel second generation oral histone deacetylase (HDAC) inhibitor. **Oncotarget** 2015 Mar 20;6(8):5735-48. (\*, equally contributed)
130. Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G\*, & Carrassa L\*. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. **Oncotarget** 2015 Nov 10;6(35):37229-40.
131. Franceschetti S, Conconi A, Aprile Von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia A, Bertoni F, Gaidano G, Cavalli F, Zucca E. Histologic Transformation In Marginal Zone Lymphomas. **Annals of Oncology**, 2015 Nov;26(11):2329-35.
132. Conconi A\*, Lobetti-Bodoni C\*, Montoto S, Lopez-Guillermo A, Coutinho R, J Matthews J, S Franceschetti S, Bertoni F, Moccia A, Rancoita PMV, Gribben J, Cavalli F, Gaidano G, Lister A, Montserrat E, Ghielmini M, & Zucca E. Life expectancy of young adults with follicular lymphoma. **Annals of Oncology**, 2015 Nov;26(11):2317-22. (\*, equally contributed)
133. Chila' R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F\*, Damia G\*, Carrassa L\* (\*, co-corresponding authors). Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for Mantle Cell Lymphoma. **Oncotarget**, 2015 Feb 20;6(5):3394-408.
134. Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudio M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G, the European T-cell

- Lymphoma Study Group, T-Cell Project. (\*, co-corresponding authors). Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in Anaplastic Large Cell Lymphoma. **Cancer Cell** 2015 Apr 13;27(4):516-32.
135. Alajati A\*, Guccini I\*, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M, Montani E, Rinaldi A, Catapano C, Bertoni F, & Alimonti A. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. **Cell Reports** 2015 Apr 28;11(4):564-76. (\*, equally contributed)
  136. Ferretti E, Di Carlo E, Ognio E, Guarnotta C, Bertoni F, Corcione A, Prigione I, Fraternali-Orcioni G, Ribatti D, Ravetti JL, Ponzoni M, and Pistoia V. Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. **Oncol Immunology** 2015 Jun 19;4(10):e1030560.
  137. Iacovelli S, Hug E, Bennardo S, Duehren-von Minden M, Rinaldi A, Gobessi S, Suljagic M, Bilbao D, Bolasco G, Eckl-Dorna J, Niederberger V, Laurenti L, Wang H, Cornall RJ, Larke SH, Croce CM, Bertoni F, Jumaa H, and Efremov DG. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. **Blood** 2015 Mar 5;125(10):1578-88.
  138. Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Brusca A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal-Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri S, Foà R, Inghirami G, Gaidano G, Rossi D. The *Krüppel-like Factor 2* transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. **Leukemia** 2015 Feb;29(2):503-7.
  139. Young Ok C, Chen J, Zijun Y, Xu-Monette ZY, Tzankov A, Ganiraju C, Manyam GC, Ling Li L, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, His ED, Choi WWL, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJM, Bertoni F, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH. Clinical Implications of Phosphorylated STAT3 Expression in de novo Diffuse Large B-cell Lymphoma. **Clinical Cancer Research** 2014, 20(19): 5113-5123.
  140. Bouska A, McKeithan T, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi A, Bertoni F, Fitzgibbon J, Fu K, Weisenburger DD, Greiner TC, Dave BJ, Gascoyne RD, Rosenwald A, Campo E, Rimsza LM, Delabie J, Jaffe ES, Braziel RM, Connors JM, Staudt LM, Chan WC. Genome-wide copy number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. **Blood**, 2014 Mar 13;123(11):1681-90.
  141. Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltran S, Mollejo M, Campos-Martin Y, Agueda L, Rinaldi A, Kwee I, Gut M, Blanc J, Oscier D, Martinez-Lopez J, Salar A, Sole F, Rodriguez-Peralto JL, Díez C, García JF, Fraga M, Sebastián E, Alvéz J, Menárguez J, González-Carrero J, Casado LF, Bayes M, Bertoni F, Gut I, & Piris MA. Whole exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. **Leukemia** 2014 Jun;28(6):1334-40.
  142. Mian M, Kwee I, Rinaldi A, Ponzoni M, Bhagat G, Rossi D, Arcaini L, Gascoyne RD, Mollejo M, Baldini L, Thieblemont C, Gaidano G, Zucca E, Bertoni F. Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. **British Journal of Haematology** 2014 Mar;164(6):896-9.
  143. Ronchetti D, Tuana G, Rinaldi A, Agnelli L, Cutrona G, Mosca L, Fabris S, Matis S, Colombo M, Gentile M, Recchia AG, Kwee I, Bertoni F, Morabito F, Ferrarini M, Neri A. Distinct Patterns of Global Promoter Methylation in Early Stage Chronic Lymphocytic Leukemia. **Genes Chromosomes and Cancer**, 2014 Mar; 53(3): 264-73.
  144. Monti S, Deambrogi S, Rinaldi A, Bertoni F, Gaidano G, Rossi D. MYC networks mutations in high risk chronic lymphocytic lymphoma. **Hematological Oncology** 2014; 32 (3):155-7.
  145. Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabò F, Piva R, Rancoita PMV, Matolcsy A, Timar B, Tousseyn T, Rodríguez-Pinilla SM, Piris MA, Beà S, Campo E, Bhagat G, Swerdlow SH, Rosenwald A, Ponzoni M, Young KH, Piccaluga PP, Dummer R, Pileri S, Zucca E, Inghirami G \*, Bertoni F \* (\*, co-corresponding authors). PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. **Blood**, 2013; 122(15): 2683-93.
  146. Bonetti P\*, Testoni M\*, Scandurra M, Ponzoni M, Piva R, Mensah AA, Rinaldi A, Kwee I, Tibiletti MG, Iqbal J, Greiner TC, Chan WC, Gaidano G, Piris MA, Cavalli F, Zucca E, Inghirami G, Bertoni F. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. **Blood**, 2013 Sep 26;122(13):2233-41. (\*, equally contributed)
  147. Chigrinova E\*, Rinaldi A\*, Kwee I, Rossi D, Rancoita PMV, Strefford JC, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, Chan WC, Orlandi E, Lucioni M, Marasca R, Inghirami G, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow SH, Stilgenbauer S, Piris MA, Matolcsy A, Spagnolo D, Eugene Nikitin E, Zamò A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Bertoni F. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter Syndrome. **Blood**, 2013; 122(15): 2673-82. (\*, equally contributed)
  148. Rinaldi A, Mensah AA, Kwee I, Forconi F, Orlandi EM, Lucioni M, Gattei V, Marasca R, Berger F, Cogliatti S, Cavalli F, Zucca E, Gaidano G, Rossi D\*, Bertoni F\* (\*, co-corresponding authors). Promoter methylation patterns in Richter Syndrome affect stem-cell maintenance and cell cycle regulation and differ from de-novo diffuse large B-cell lymphoma. **British Journal of Haematology** 2013; 163(2):194-204.
  149. De Campos C.P., Rancoita PMV, Kwee I, Zucca E, Zaffalon M., Bertoni F. Discovering subgroups of patients from DNA copy number data using NMF on compact matrices. **PLOS One** 2013 Nov 20;8(11):e79720. doi: 10.1371/journal.pone.0079720. eCollection 2013.
  150. Mian M, Rinaldi A, Mensah AA, Rossi D, Ladetto M, Forconi F, Marasca R, Uhr M, Stussi G, Kwee I, Cavalli F, Gaidano G, Zucca E, Bertoni F. Large genomic aberrations detected by SNP-array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. **Annals of Oncology** 2013; 23: 729-735.
  151. Rinaldi A, Kwee I, Young KH, Zucca E, Gaidano G, Forconi F\*, Bertoni F\* (\*, co-corresponding authors). Genome-wide high resolution DNA profiling of hairy cell leukaemia. **British Journal of Haematology** 2013; 162(4): 566-569.
  152. Aprile von Hohenstaufen K., Conconi A, de Campos CP, Franceschetti S, Bertoni F, Margiotta Casalucci G, Stathis A, Ghilemini M, Stussi G, Cavalli F, Gaidano G, Zucca E. Prognostic impact of monocyte count at presentation in mantle cell lymphoma. **British Journal of Haematology** 2013; 162(4): 465-73.
  153. Li ZM, Spagnuolo L, Mensah AA, Rinaldi A, Bhagat G, Zucca E, Doglioni C, Ferreri AJM, Ponzoni M, Bertoni F. Gains of *CCND3* gene in ocular adnexal MALT lymphomas: an integrated analysis. **British Journal of Haematology** 2013; 160 (5): 719-722.
  154. Rossi D, Rasi S, Spina V, Brusca A, Monti S, Ciardullo C, Deambrogi C, Khiabani H, Serra R, Bertoni F, Forconi F, Laurenti L, Marasca R, Dal-Bo M, Rossi FM, Bulian P, Nomdedeu J, Del Poeta G, Gattei V, Pasqualucci L, Rabadan R, Foà R, Dalla Favera R, Gaidano G. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. **Blood** 2013; 121(8): 1403-1412.
  155. Conconi A, Franceschetti S, Lobetti-Bodoni C, Stathis A, Margiotta Casalucci G, Ramponi A, Mazzucchelli L, Bertoni F,

- Ghielmini M, Gaidano G, Cavalli F, Zucca E. Risk factors of central nervous system relapse in mantle cell lymphoma. **Leukemia and Lymphoma** 2013 Sep; 54(9): 1908-14.
156. Copie-Bergman C, Wotherspoon AC, Capella C, Motta T, Pedrinis E, Pileri SA, Bertoni F, Conconi A, Zucca E, Ponzoni M, Ferreri AJM. GELA Histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. **British Journal of Haematology** 2013; 160 (1): 47-52.
157. De Paoli L, Cerri M, Monti S, Rasi S, Spina V, Brusca G, Grego M, Ciardullo C, Fama' R, Martini M, Laurenti L, Forconi F, Marasca R, Larocca LM, Bertoni F, Gaidano G, Rossi D. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. **Leukemia And Lymphoma** 2013 May; 54(5):1087-90.
158. Rossi D, Trifonov V, Fangazio M, Brusca G, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, A. Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G. The coding genome of splenic marginal zone lymphoma: Activation of NOTCH2 and other pathways regulating marginal zone development. **The Journal of Experimental Medicine** 2012; 202 Aug 27;209(9):1537-51.
159. Mian M, Scandurra M, Chigrinova E, Shen Y, Inghirami G, Greiner TC, Chan WC, Vose JM, Testoni M, Chiappella A, Baldini L, Ponzoni M, Ferreri AJM, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Uccella S, Tibiletti MG, Zucca E, Kwee I, Bertoni F. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. **Annals of Oncology** 2012; 23(3): 729-735.
160. Kwee I, Capello D, Rinaldi A, Rancoita PMV, Bhagat G, Greiner TC, Spina M, Ghoghini A, Chan WC, Paulli M, Zucca E, Tirelli U, Carbone A, Gaidano G, Bertoni F. Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphomas. **Leukemia and Lymphoma** 2012 Jan;53(1):71-6.
161. Kwee I, Rinaldi A, Rancoita P, Rossi D, Capello D, Forconi F, Giuliani N, Piva R, Inghirami G, Gaidano G, Zucca E, Bertoni F. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. **British Journal of Haematology** 2012;156(3):354-357.
162. Li ZM, Rinaldi A, Cavalli A, Mensah AA, Ponzoni M, Gascoyne R, Bhagat G, Zucca E, Bertoni F. MYD88 somatic mutations in MALT lymphomas. **British Journal of Haematology** 2012 Sep;158(5):662-4.
163. Mensah AA, Rinaldi A, Ponzoni M, Canzonieri V, Uccella S, Rossi D, Bhagat G, Gaidano G, Zucca E, Bertoni F. Absence of *NOTCH1* gene mutations in MALT lymphomas. **British Journal of Haematology** 2012 May;157(3):382-4.
164. Mian M, Rinaldi A, Mensah AA, Rossi D, Ladetto M, Forconi F, Marasca R, Gattei V, Zucca E, Cavalli F, Gaidano G, Kwee I, Bertoni F. Del(13q14.3) length matters: an integrated analysis of genomic, FISH and clinical data in 169 chronic lymphocytic leukemia patients with 13q deletion alone or normal karyotype. **Hematological Oncology** 2012 Mar;30(1):46-9.
165. Ferreri AJM, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, Montalbán C, Stelitano C, Cabrera ME, Resti AG, Politi LS, Doglioni C, Cavalli F, Zucca E, Ponzoni M, Dolcetti R on behalf of the International Extranodal Lymphoma Study Group (IELSG). *Chlamydomyces Psittaci* Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial. **Journal of Clinical Oncology** 2012 Aug 20;30(24):2988-94.
166. Conconi A, Ponzio, Lobetti-Bodono C, Motta M, Rancoita PMV, Stathis A, Moccia AA, Mazzucchelli L, Bertoni F, Ghielmini M, Cavalli F, Zucca E. Incidence, risk factors and outcome of histologic transformation in follicular lymphoma. **British Journal of Haematology** 2012 Apr;157(2):188-96.
167. Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich P-Y, Hitz F, Bargetzi M, Mingrone V, Martinelli G, Trojan A, Bouabdallah K, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, and Ketterer N on behalf of the Swiss SAKK and the French GOELAMS group from the European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. **Haematologica** 2012 Jul;97(7):1085-91.
168. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Brusca G, Spina V, Deambrogi C, Marinelli M, Famà R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, Pasqualucci L, Guarini A, Dalla-Favera R, Foà R, Gaidano G. Disruption of *BIRC3* associates with fludarabine chemorefractoriness in TP53 wild type chronic lymphocytic leukemia. **Blood** 2012; 119(12): 2584-2862.
169. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, Ponzoni M, Zamò A, Iqbal J, Piccaluga PP, Neri A, Chan WC, Pileri S, Bertoni F, Inghirami G, Piva R, on behalf of the European T-Cell Lymphoma Study Group. Identification of a three-gene model as a powerful diagnostic tool for the recognition of ALK negative ALCL. **Blood** 2012 Aug 9;120(6):1274-1281.
170. Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, Rossi D, Barbiero S, Mantoan B, Mantella E, Zanni M, Ghione P, Larocca A, Passera R, Bertoni F, Gattei V, Forconi F, Laurenti L, Del Poeta G, Marasca R, Cortelazzo S, Gaidano G, Palumbo A, Boccadoro, Ladetto M. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. **Haematologica** 2012 Jun;97(6):849-53.
171. Bulian P, Rossi D, Forconi F, Del Poeta, Bertoni F, Zucca E, Montillo M, Pozzato G, D'Arena G, Efremov D, Marasca R, Lauria F, Gaidano G, Gattei V, Laurenti L. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. **Journal of Translational Medicine** 2012 Jan 30;10:18.
172. Rossi D, Spina V, Forconi F, Capello D, Martini M, Gattei V, Ramponi A, Larocca LM, Bertoni F, Gaidano G. Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. **International Journal of Cancer** 2012 Jun 15;130(12):3006-10.
173. Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo C. An open-label, phase 2 study of biweekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum containing regimens. **International Journal of Gynecological Cancer** 2012 Jun;22(5):792-800.
174. Rinaldi A, Mian M, Chigrinova E, Arcaini L, Bhagat G, Novak U, Rancoita PMV, De Campos C, Forconi F, Gascoyne R, Facchetti F, Ponzoni M, Govi S, Ferreri AJ, Mollejo M, Piris MA, Baldini L, Soulier J, Thieblemont C, Canzonieri V, Gattei V, Marasca R, Franceschetti S, Gaidano G, Tucci A, Uccella S, Tibiletti MG, Dimhofer S, Tripodo C, Doglioni C, Dalla-Favera R, Cavalli F, Zucca E, Kwee I, Bertoni F. Genome wide DNA-profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. **Blood** 2011; 117(5):1595-604.
175. Rinaldi A, Mian M, Kwee I, Rossi D, De Ambrogi C, Mensah AA, Forconi F, Spina V, Cencini E, Drandi D, Ladetto M, Santachiara R, Marasca R, Gattei V, Cavalli F, Zucca E, Gaidano G, Bertoni F. Genome-wide DNA profiling better defines the

- prognosis of chronic lymphocytic leukaemia. **British Journal of Haematology** 2011; 154 (5): 590-599.
176. Kwee I, Rancoita PMV, Rinaldi A, Ferreri AJM, Bhagat G, Gascoyne R, Canzonieri V, Gaidano G, Doglioni C, Zucca E, Ponzoni M, Bertoni F. Genomic profiles of MALT lymphomas: variability across anatomic sites. **Haematologica** 2011; 96 (7): 1064-1066.
  177. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, Cresta S, Gargiulo E, Forconi F, Guarini A, Arcaini L, Paulli M, Laurenti L, Larocca LM, Marasca R, Gattei V, Oscier D, Bertoni F, Mullighan CG, Foà R, Pasqualucci L, Rabadan R, Dalla Favera R, Gaidano G. Analysis of the Chronic Lymphocytic Leukemia Coding Genome: Role of NOTCH1 Mutational Activation. **The Journal of Experimental Medicine** 2011; 208 (7): 1389-401.
  178. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscazzin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, A. Pileri SA, Foà R, Bertoni F, Dalla-Favera R, Pasqualucci L, Gaidano G. Alteration of BIRC3 and multiple other NF-kb pathway genes in splenic marginal zone lymphoma. **Blood** 2011;118(18):4930-4.
  179. Rossi D, Bruscazzin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, Del Giudice I, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, Pasqualucci L, Foà R, Dalla-Favera R, Gaidano G. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. **Blood** 2011;118(26):6904-8.
  180. Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, Arcaini A, Lucioni M, Rocque GB, Xu-Monette ZY, Visco C, Chang J, Chigrinova E, Forconi F, Marasca R, Besson C, Papadaki T, Paulli M, Larocca LM, Pileri SA, Gattei V, Bertoni F, Foà R, Young KY, Gaidano G. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival post-transformation. **Blood** 2011 Mar 24; 117(12): 3391-401.
  181. Chigrinova E, Mian M, Shen Y, Greiner TC, Chan WC, Vose JM, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJM, Franceschetti S, Gaidano G, Tucci A, Facchetti F, Lazure T, Lambotte O, Montes-Moreno S, Piris MA, Zucca E, Kwee I, Bertoni F. Integrated Profiling of Diffuse Large B-cell Lymphoma with 7q gain. **British Journal of Haematology** 2011 May; 153(4): 499-503.
  182. Testoni M, Kwee I, Greiner TC, Montes-Moreno S, Vose J, Chan WC, Chiappella, Baldini L., Ferreri AJM, Gaidano G, Mian M, Zucca E, Bertoni F. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. **British Journal of Haematology** 2011 Oct;155(2): 274-277.
  183. Chigrinova E, Mian M, Scandurra M, Greiner TC, Chan WC, Vose JM, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJM, Franceschetti S, Gaidano G, Tucci A, Facchetti F, Lazure T, Lambotte O, Montes-Moreno S, Piris MA, Nomdedeu JF, Uccella S, Rancoita PMV, Kwee I, Zucca E, Bertoni F. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. **Hematological Oncology** 2011 Mar; 29(1): 38-41.
  184. Rinaldi A, Ponzoni M, Uccella S, Rossi D, Gaidano G, Facchetti F, Pruneri G, Tibiletti MG, Capella C, Zucca E, Doglioni C, Catapano C, Bertoni F. In vitro efficacy of tyrosine kinase inhibitors: Syk and Bcr/Abl inhibitors in lymphomas. **Hematological Oncology** 2011 Sep;29(3):164-6.
  185. Poretti G, Kwee I, Bernasconi B, Rancoita PMV, Rinaldi A, Capella C, Zucca E, Neri A, Tibiletti MG, Bertoni F. Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. **Leukemia Research** 2011 Jun;35(6):808-13.
  186. Dal Bo M, Rossi F M, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, Palumbo G, Nanni M, Rinaldi R, Kwee I, Tissino E, Corradini G, Gozzetti A, Cencini A, Ladetto M, Coletta AM, Luciano F, Bulian P, Pozzato G, Laurenti L, Forconi F, Di Raimondo F, Marasca R, Del Poeta G, Gaidano G, Foà R, Guarini A and Gattei V. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. **Genes, Chromosomes and Cancer** 2011 Aug; 50(8): 633-643.
  187. Capello D, Gloghini A, Martini M, Spina U, Tirelli U, Bertoni F, Rinaldi A, Morra E, Rambaldi A, Sinigaglia F, Larocca LM, Carbone A. Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin's lymphomas. **British Journal of Haematology** 2011 Mar; 152(6): 777-80.
  188. Bulian P, Tarnani M, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, Deaglio S, D'Arena G, Efremov DG, Marasca R, Lauria F, Gattei V, Gaidano G, Laurenti L. Multicenter validation of a prognostic index for overall survival in chronic lymphocytic leukemia. **Hematological Oncology** 2011 Jun;29(2): 91-99.
  189. Rasi S, Bruscazzin A, Rinaldi A, Cresta S, Fangazio M, De Paoli L, Monti S, Gargiulo E, Kwee I, Foà R, Bertoni F, Gaidano G, Rossi D. Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. **Leukemia Research** 2011 Oct; 35(10):1419-1422.
  190. Furlan D, Carnevali I, Bernasconi B, Sahnane N, Milani K, Cerutti R, Bertolini V, Chiaravalli AM, Bertoni F, Kwee I, Capella C. Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically relevant groups of colorectal carcinomas. **Modern Pathology** 2011; 24(1): 126-137.
  191. Zhang H-L, Wang H-Q, Hao, X-S, Capello D, Cogliatti SB, Bertoni F, Cavalli F. Biased immunoglobulin genes rearrangement in mantle cell lymphoma: Hints to identify the normal B-cell counterpart. **Clinical Oncology and Cancer Research** 2011; 8: 65-70.
  192. Scandurra M, Mian M, Greiner TC, Rancoita PMV, De Campos CP, Chan WC, Vose JM, Chigrinova E, Inghirami G, Chiappella A, Baldini L, Ponzoni M, Ferreri AJM, Franceschetti S, Gaidano G, Montes-Moreno S, Piris MA, Facchetti F, Tucci A, Nomdedeu JF, Lazure T, Lambotte O, Uccella S, Pinotti G, Pruneri G, Martinelli G, Young KH, Tibiletti MG, Rinaldi A, Zucca E, Kwee I, Bertoni F. Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP. **British Journal of Haematology** 2010; 151(3): 221-231.
  193. Rinaldi A, Capello D, Scandurra M, Greiner TC, Chan WC, Bhagat G, Rossi D, Morra E, Paulli M, Rambaldi A, Rancoita PMV, Inghirami G, Ponzoni M, Moreno SM, Piris MA, Mian M, Chigrinova E, Zucca E, Dalla Favera R, Gaidano G, Kwee I, Bertoni F. SNP-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. **British Journal of Haematology** 2010;149(4): 569-577.
  194. Capello D, Scandurra M, Poretti G, Rancoita PMV, Mian M, Gloghini A, Deambrogi C, Martini M, Rossi D, Greiner TC, Chan WC, Ponzoni M, Montes Moreno S, Piris MA, Canzonieri V, Spina M, Tirelli U, Inghirami G, Rinaldi A, Zucca E, Dalla Favera R, Cavalli F, Larocca LM, Kwee I, Carbone A, Gaidano G, Bertoni F. Genome wide DNA-profiling of HIV-related B-cell lymphomas. **British Journal of Haematology** 2010; 148(2):245-255.
  195. Rinaldi A, Forconi F, Arcaini A, Mian M, Sozzi E, Zibellini S, Baldini L, Franceschetti S, Gaidano G, Marasca R, Mollejo M, Piris MA, Tucci A, Facchetti F, Bhagat G, Dalla Favera R, Rancoita PMV, Zucca E, Kwee I, Bertoni F. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. **British Journal of Haematology** 2010;151(5):435-9.
  196. Chigrinova E, Kwee I, Rinaldi A, Poretti G, Pruneri G, Neri A, Gaidano G, Ponzoni M, Zucca E, Bertoni F. Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. **British**

- Journal of Haematology** 2010; 150(2): 229-232.
197. Rancoita PMV, Hutter M, Bertoni F, Kwee I. An integrated Bayesian analysis of LOH and copy number data. **BMC Bioinformatics** 2010; 11: 321 (32 pages).
  198. Scandurra M, Rossi D, Deambrogi C, Rancoita PMV, Chigrinova E, Mian M, Cerri M, Rasi S, Sozzi E, Forconi F, Ponzoni M, Montes-Moreno S, Piris MA, Inghirami G, Zucca E, Gattei V, Rinaldi A, Kwee I, Gaidano G, Bertoni F. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. **Hematological Oncology** 2010; 28(2): 62-67.
  199. Ponzoni M, Uccella S, Mian M, Rinaldi A, Facchetti F, Pruneri G, Gaidano G, Capella C, Zucca E, Doglioni C, Bertoni F. Syk expression patterns differ among B-cell lymphomas. **Leukemia Research** 2010; 34(9): e243-245.
  200. Bomben R, Dal Bo M, Benedetti D, Capello D, Forconi F, Marconi D, Bertoni F, Maffei R, Laurenti L, Rossi R, Del Principe MI, Luciano F, Sozzi E, Cattarossi I, Zucchetto A, Rossi FM, Bulian P, Zucca E, Nicoloso MS, Degan M, Marasca R, Efremov DG, Del Poeta G, Gaidano G, Gattei V. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. **Clinical Cancer Research** 2010; 16(2):620-8.
  201. Bomben R, Dal Bo M, Capello D, Forconi F, Bertoni F, Maffei R, Laurenti L, Rossi D, Zucca E, Degan M, Marasca R, Efremov DG, Del Poeta G, Gaidano G, Gattei V. IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. **British Journal of Haematology** 2010; 149(2):299-302.
  202. Rinaldi A, Chiaravalli AM, Mian M, Zucca E, Tibiletti MG, Capella C, Bertoni F. The Serotonin Receptor 3A (HTR3A) expression in normal and neoplastic B-cells. **Pathobiology** 2010; 77(3): 129-135.
  203. Venetz D, Ponzoni M, Ferreri AJM, Bertoni F, Doglioni C, Ugucioni M. Perivascular chemokine expression regulates T cell recruitment and angiocentric positioning of malignant B cells in Primary Central Nervous System Lymphoma. **International Journal of Cancer** 2010; 127(10): 2300-2312.
  204. Zibellini S, Capello D, Forconi F, Marcatili P, Rossi D, Rattotti S, Franceschetti S, Sozzi E, Cencini E, Marasca R, Baldini L, Tucci A, Bertoni F, Passamonti F, Orlandi E, Varettoni M, Merli M, Gattei V, Tramontano A, Paulli M, Gaidano G, Arcaini L. Stereotyped Patterns of B cell receptor in Splenic Marginal Zone B-Cell Lymphoma. **Haematologica** 2010 Oct; 95(10): 1792-1796.
  205. Conconi A, Motta M, Bertoni F, Piona C, Stathis A, Wannesson L, Gracia E, Belisario Filho V, Rodriguez Abreu D, Froesch P, Mazzucchelli L, Ghielmini M, Cavalli, Zucca E. Patterns of survival of follicular lymphomas at a single institution through three decades. **Leukemia and Lymphoma** 2010; 51(6): 1028-1034.
  206. Bilous N, Bomben R, Dal Bo M, Capello D, Forconi F, Laurenti L, Bertoni F, Efremov DG, Marasca R, Del Poeta G, Martina Z, Kryachouk I, Kryachouk I, Gaidano G, Chumak A, Gattei V, Abramenko I. Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B cell receptors in an Ukrainian cohort. **Leukemia and Lymphoma** 2010; 51(5): 822-838.
  207. Cro L, Ferrario A, Lionetti M, Bertoni F, Zucal N, Nobili L, Fabris S, Todoerti K, Cortelezzi A, Guffanti A, Goldaniga M, Marcheselli L, Neri A, Lambertenghi-Deliliers G, Baldini L. The clinical and biological features of a series of immunophenotypic variant of B-CLL. **European Journal of Haematology** 2010; 85(2): 120-129.
  208. Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PMV, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla Favera R, Pasqualucci L, Bhagat G, Bertoni F. The NF-KB negative regulator TNFAIP3 (A20) is commonly inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas. **Blood** 2009; 113(20): 4918-4921.
  209. Rancoita PMV, Hutter M, Bertoni F, Kwee I. Bayesian DNA copy number analysis. **BMC Bioinformatics** 2009 Jan 8: 10:10 (19 pages).
  210. Compagno M, Lim WK, Grunn A, Nandula SV, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla Favera R, Pasqualucci L. Mutations at multiple genes cause deregulation of the NF-kB pathway in diffuse large B-cell lymphoma. **Nature** 2009;459(7247):717-21.
  211. Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri S, Lauria F. Hairy cell leukemias (HCL) with unmutated IgHV genes define the minor subset refractory to single agent Cladribine and with more aggressive behavior. **Blood** 2009; 114(21): 4696-702.
  212. Tibiletti MG, Martin V, Bernasconi B, Del Curto B, Pecciarini L, Uccella S, Pruneri G, Ponzoni M, Mazzucchelli L, Martinelli G, Ferreri A, Pinotti G, Assannelli A, Scandurra M, Doglioni C, Zucca E, Capella C, Bertoni F. BCL2, BCL6, MYC, MALT1 and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of FISH probes and correlation with clinical outcome. **Human Pathology** 2009; 40 (5): 645-652.
  213. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu J, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. **Clinical Cancer Research** 2009; 15(13): 4415-4422.
  214. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, Todoerti K, Verdelli D, Battaglia C, Bertoni F, Lambertenghi Deliliers G, Neri A. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. **Genes, Chromosomes and Cancer** 2009; 48(7):603-14.
  215. Rossi D, Sozzi E, Puma A, De Paoli L, Rasi S, Spina V, Gozzetti A, Tassi M, Cencini E, Raspadori D, Pinto V, Bertoni F, Gattei V, Lauria F, Gaidano G, Forconi F. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. **British Journal Haematology** 2009;146(1):64-75.
  216. Rossi R, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, Ramponi A, Chiappella A, Pogliani EM, Vitolo U, Kwee I, Bertoni F, Conconi A, Gaidano G. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. **Leukemia** 2009; 23(6):1118-26.
  217. Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, Cavalli F, Pinotti G, Zucca E. Long-term outcome following *Helicobacter pylori* eradication in a series of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. **Annals of Oncology** 2009;20(6):1086-93.
  218. Hitz F, Martinelli G, Zucca E, von Moos R, Mingrone W, Simcock M, Peterson J, Cogliatti SB, Bertoni F, Zimmermann DR, Ghielmini M on behalf of SAKK. A multicenter phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. **Hematological Oncology** 2009; 27(3): 154-159.
  219. Bomben R, Dal-Bo M, Capello D, Forconi F, Maffei R, Laurenti L, Rossi D, Del-Principe MI, Zucchetto A, Bertoni F, Rossi,

- FM, Bulian B, Cattarossi I, Ilariucci F, Sozzi E, Spina V, Zucca E, Degan D, Lauria F, Del-Poeta G, Efremov DG, Marasca R, Gaidano G, Gattei VG. Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B cell receptors: results from an Italian multicenter study. **British Journal Haematology** 2009; 144 (4): 492-506.
220. Forconi F, Rinaldi A, Kwee I, Sozzi E, Raspadori D, Rancoita PMV, Scandurra M, Rossi D, Deambrogi C, Capello D, Zucca E, Marconi D, Bomben R, Gattei V, Lauria F, Gaidano G, Bertoni F. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. **British Journal Haematology** 2008; 143(4): 532-536.
221. Forconi F, Poretti G, Kwee I, Sozzi E, Rossi D, Rancoita PMV, Capello D, Rinaldi A, Zucca E, Raspadori D, Spina V, Lauria F, Gaidano G, Bertoni F. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. **British Journal Haematology** 2008; 141(5): 622-630.
222. Lozza L, Rivino L, Guarda G, Jarrossay D, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A, Geginat J. The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion and lineage commitment of primed human CD4+IL-7Rhi T cells. **European Journal of Immunology** 2008; 38(1): 30-39.
223. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, Maccioni E, Tosi D, Gianni L. Phase I of bortezomib with weekly paclitaxel in patients with advanced solid tumors. **European Journal Of Cancer** 2008; 44(13): 1829-1834.
224. Furlan D, Sahnane N, Carnevali I, Cerutti R, Bertoni F, Kwee I, Uccella S, Bertolini V, Chiaravalli AM, Capella C. Up-regulation of the HIF-1 transcriptional pathway in colorectal carcinomas. **Human Pathology** 2008; 39 (10): 1483-1494.
225. Pruneri G, Alietti A, Agnelli L, Morabito F, Laszlo D, Calabrese L, Fabris S, Bertolini F, Agazzi A, Bottiglieri L, Rafaniello Raviele P, Baldini L, Pileri S, M.D., Sabattini E, Bosari S, Maisonneuve P, Lambertenghi-Deliliers G, Bertoni F, Martinelli G, Viale G, Neri A. Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. **Leukemia Research** 2008; 32(10): 1628-1632.
226. Fabris S, Todoerti K, Mosca L, Agnelli L, Intini D, Lionetti M, Gueneri S, Lambertenghi-Deliliers G, Bertoni F, Neri A. Molecular and Transcriptional Characterization of the Novel 17p11.2-p12 Amplicon in Multiple Myeloma. **Genes, Chromosomes and Cancer** 2007; 46 (12): 1109-1118.
227. Lacrima K, Rinaldi A, Vignati S, Martin V, Tibiletti MG, Gaidano G, Catapano CV, Bertoni F. Cyclin-dependent kinase inhibitor seliciclib shows *in vitro* activity in diffuse large B cell lymphomas. **Leukemia and Lymphoma** 2007; 48(1): 158-167.
228. Gracia E, Froesch P, Mazzucchelli L, Martin V, Rodríguez-Abreu D, Jiménez J, Melgares M, Santos D, Capó V, Cavalli F, Zucca E, Bertoni F. Low prevalence of *Chlamydia psittaci* in ocular adnexal lymphomas from Cuban patients. **Leukemia and Lymphoma** 2007; 48(1): 104-108.
229. Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano CV, Tibiletti MG, Bertoni F. Concomitant *MYC* and microRNA cluster miR-17-92 (*C13orf25*) amplification in human mantle cell lymphoma. **Leukemia and Lymphoma** 2007; 48(2): 410-412.
230. Tibiletti MG, Milani K, Martin V, Zucca E, Motta T, Cortelazzo S, Pinotti G, Mazzucchelli L, Pruneri G, Martinelli G, Barbazza R, Capella C, Bertoni F on behalf of the International Extranodal Lymphoma Study Group (IELSG). Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type. **Hematological Oncology** 2007; 25: 184-188.
231. Ponzoni M, Kwee I, Mazzucchelli L, Ferreri AJM, Zucca E, Doglioni C, Cavalli F, Bertoni F. A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals. **Pathobiology** 2007; 74(4): 264-269.
232. Lombardi K, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S, Kwee I, Rinaldi A, Ronchetti D, Verdelli D, Lambertenghi-Deliliers G, Bertoni F, Neri A. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. **Genes, Chromosomes and Cancer** 2007; 46(3): 226-238.
233. Li L, Ryser S, Dizin E, Pils D, Krainer M, Jefford CE, Bertoni F, Zellinger R, Irminger-Finger I. Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers. **Cancer Research** 2007; 67(24): 11876-11885.
234. Agnelli L, Bicciato S, Fabris S, Baldini L, Morabito F, Intini D, Verdelli D, Callegaro A, Bertoni F, Lambertenghi-Deliliers G, Lombardi L, Neri A. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. **Haematologica** 2007; 92:56-65.
235. Ponzoni M, Berger F, Chassagne-Clement C, Tinguely M, Jouvet A, Ferreri AJM, Dell'Oro S, Terreni MR, Doglioni C, Weis J, Cerati M, Milani M, Iuzzolino P, Motta T, Carbone A, Pedrinis E, Sanchez J, Blay JY, Reni M, Conconi A, Bertoni F, Zucca E, Cavalli F, Borisch B. on behalf of the International Extranodal Lymphoma Study group (IELSG). Reactive perivascular T-cell infiltrate predicts survival in primary CNS B-cell lymphomas. **British Journal Haematology** 2007; 138(3): 316-23.
236. Campidelli C, Sabattini E, Piccioli M, Rossi M, De Blasi D, Miraglia E, Rodriguez-Abreu D, Francini LL, Bertoni F, Mazzucchelli L, Cavalli F, Zucca E, Pileri SA. Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. **Human Pathology** 2007; 38(5): 787-92.
237. Rinaldi A, Kwee I, Poretti G, Mensah A, Pruneri G, Capello D, Rossi D, Zucca E, Ponzoni M, Catapano C, Tibiletti MG, Paulli M, Gaidano G, Bertoni F. Comparative genome wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. **British Journal Haematology** 2006; 134: 27-36.
238. Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, Poretti G, Gaidano G, Calabrese G, Martinelli G, Baldini L, Pruneri G, Capella C, Zucca E, Cotter FE, Cigudosa JC, Catapano CV, Maria Grazia Tibiletti MG, Bertoni F. Genomic and expression profiling identifies the B cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. **British Journal Haematology** 2006; 132: 303-316.
239. Taborelli M, Tibiletti MG, Martin V, Pozzi B, Bertoni F, Capella C. Chromosome band 6q deletion pattern in malignant lymphomas. **Cancer Genetics and Cytogenetics** 2006; 165: 106-113.
240. Macagno A., Molteni M., Rinaldi A., Bertoni F., Lanzavecchia A., Rossetti C., Sallusto F. A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. **The Journal of Experimental Medicine** 2006; 203: 1481-1492.
241. Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, Nur-e-Alam M, Bergant J, Bertoni F, Carbone GM, Rohr J, Catapano CV. Novel GC-rich DNA binding compound produced by a genetically engineered mutant of the mithramycin producer *S. Argillaceus* exhibits improved transcriptional repressor activity: implications for cancer therapy. **Nucleic Acids Research** 2006; 34: 1721-1734.
242. Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C, Bertoni F, Carbone GM, Catapano CV. Cellular effects and transcriptional response to peroxisome proliferator-activated receptor  $\gamma$  activation in ovarian cancer cells. **Neoplasia** 2006; 8: 251-261.
243. Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E, Catapano C, Cavalli F, Gianella-Borradori A, MacCallum

- DE, Bertoni F. *In vitro* activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. **Annals of Oncology** 2005; 16: 1169-1176.
244. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected TLR agonist combinations synergistically trigger dendritic cells with enhanced T<sub>H</sub>1 polarizing capacity. **Nature Immunology** 2005; 6: 779-776.
245. Chtanova T, Newton R, Liu S, Weininger L, Young TR, Silva DG, Bertoni F, Rinaldi A, Chappaz S, Sallusto F, Rolph MS, Mackay CR. Identification of T cell-restricted responses, using a comprehensive collection of microarray datasets. **The Journal of Immunology** 2005; 175: 7837-7847.
246. Cogliatti SB, Bertoni F, Zimmermann DR, Henz S, Diss TC, Ghielmini M and Schmid U. *IgV<sub>H</sub>* mutations in blastoid mantle cell lymphoma characterize a subgroup with tendency to a more favourable clinical outcome. **Journal of Pathology** 2005; 206: 320-327.
247. Ghielmini M, Hsu Schmitz S-F, Cogliatti S, Bertoni F, Waltzer U, Fey M, Betticher D, Schäfer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T. Effect of single agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma. **Journal of Clinical Oncology** 2005; 23: 705-711.
248. Laszlo D, Andrés JM Ferreri AJM, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E. Clinical activity of rituximab in gastric marginal zone (MALT) non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. **Journal of Clinical Oncology** 2005; 23: 1979-1983.
249. Martinelli G, Laszlo D, Agazzi A, Pruneri G, Bertoni F, Calabrese L, Martinelli G. In Reply to; "Persistent Residual Disease in t(11;18)(q21;q21) Positive Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Chemotherapy or Rituximab". **Journal of Clinical Oncology** 2005; 23: 7363-7364.
250. Auer R, Starczynski J, McElwaine SM, Bertoni F, Newland A, Fegan D, Cotter. Identification of a potential role for BOB-1 and PC3b in the 11q23 deletion of CLL. **Genes, Chromosomes and Cancer** 2005;43: 1-10.
251. Bertoni F, Conconi A, Cogliatti S, Hsu Schmitz SF, Ghielmini M, Cerny T, Fey M, Pichert G, Bertolini F, Ponzoni M, Baldini L, Jones C, Auer R, Zucca E, Cavalli, Cotter FE. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). **British Journal of Haematology** 2004; 124: 289-298.
252. Grossfeld PD, Mattina T, Lai Z, Favier R, Lyons Jones K, Cotter F, Jones C, and the 11q Consortium (Adam M, Bertoni F, Bellugi U, Bradshaw C, Chen J, Dell'Aquila M, Elias W, Haghi M, Hoffman H, Jockin Y, Lee Jones K, Jones M, Jones W, Lavine J, Ruiz-Lozano P, Magit A, Newton P, Nyhan W, Oakley D, O'Halloran H, Rothman A, Scher C, Tunnacliffe A, Zingale A). The 11q terminal deletion disorder: A prospective study of 110 cases. **American Journal of Medical Genetics Part A** 2004; 129A: 51-61.
253. Fu W-N, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, Jia L. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. **Oncogene** 2003; 22: 451-455.
254. Favier R, Jondeau K, Boutard P, Grossfeld P, Reinert P, Jones C, Bertoni F, Cramer EM. Paris-Trousseau syndrome: clinical, hematological, molecular data of ten new cases. **Thrombosis and Haemostasis** 2003; 90:893-897.
255. Bertoni F, Conconi A, Capella C, Motta T, Giardini R, Ponzoni M, Pedrinis E, Domenico Novero D, Rinaldi P, Cazzaniga G, Biondi A, Wotherspoon A, Hancock W, Smith P, Souhami R, Cotter FE, Cavalli F, Zucca E. Molecular follow-up in gastric MALT lymphomas: early analysis from of the LY03 cooperative trial. **Blood** 2002; 99: 2541-2544.
256. Auer RL, Bertoni F, Jones C, Cotter FE. The Class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23. **Leukemia** 2002; 16: 1396-1397.
257. Conconi A, Bertoni F, Pedrinis E, Motta T, Roggero E, Luminari S, Capella C, Bonato M, Cavalli F, Zucca E. Nodal marginal zone B cell lymphomas may arise from different subsets of marginal zone B lymphocytes. **Blood** 2001; 98: 781-786.
258. Bertoni F, Conconi A, Luminari S, Realini C, Roggero E, Baldini L, Carobbio S, Neri A, Cavalli F, Zucca E. Lack of *CD95/FAS* gene somatic mutations in marginal zone B-cell lymphomas. **Leukemia** 2000; 14: 446-448.
259. Luminari S, Intini D, Baldini L, Berti E, Bertoni F, Zucca E, Cro L, Maiolo AT, Cavalli F, Neri A. Analysis of *BCL10* gene mutations in lymphoid malignancies. **Leukemia** 2000; 14: 905-908.
260. Roggero E; Zucca E, Mainetti C, Bertoni F, Valsangiacomo C, Pedrinis E, Borisch B, Piffaretti JC, Cavalli F, Isaacson PG. Eradication of *Borrelia burgdorferi* infection in primary marginal zone B-cell lymphoma of the skin. **Human Pathology** 2000; 31: 263-268.
261. Ghielmini M, Schmitz SF, Bürki K, Pichert G, Betticher DC, Stupp R, Wernli M, Lohri A, Schmitter D, Bertoni F, Cerny T for the Swiss Group for Clinical Research (SAKK). The effect of Rituximab on patients with follicular and mantle-cell lymphoma. **Annals of Oncology** 2000; 11 (suppl. 1): S123-S126.
262. Zucca E, Roggero E, Maggi-Solcà N, Conconi A, Bertoni F, Reilly I, Castelli D, Pedrinis E, Piffaretti JC, Cavalli F. Prevalence of *Helicobacter pylori* and Hepatitis C Virus (HCV) infections among non-Hodgkin's lymphoma patients in Southern Switzerland. **Haematologica** 2000; 85: 147-153.
263. Bertoni F, Conconi A, Carobbio S, Realini C, Codegioni AM, Zucca E, Cavalli F. Analysis of *CD95/FAS* gene somatic mutations in ovarian cancer cell lines. **International Journal of Cancer** 2000; 86: 450.
264. Bertoni F, Sanna P, Tinguely M, Roggero E, Conconi AR, Gisi M, Cazzaniga G, Biondi A, Pedrinis E, Cavalli F, Zucca E. Association of gastric and Waldeyer's ring lymphoma: a molecular study. **Hematological Oncology** 2000; 18: 15-19.
265. Conconi A, Zucca E, Roggero E, Bertoni F, Bernasconi A, Mingrone W, Pedrinis E, Cavalli F. Prognostic models for diffuse large B-cell lymphoma. **Hematological Oncology** 2000; 18: 61-73.
266. Bertoni F, Müllenbach R, Brogгинi M, Roggero E, Cavalli F, Cotter FE, Zucca E. Extranodal marginal zone B-cell lymphoma genotyping by ALU - polymerase chain reaction. **Leukemia and Lymphoma** 2000; 38: 605-610.
267. Bertoni F, Gisi M, Roggero E, Conconi A, Mingrone W, Cavalli F, Zucca E. Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma. **Digestive Liver Disease** 2000; 32: 188-191.
268. Bertoni F, Codegioni AM, Furlan D, Tibiletti MG, Capella C, Brogгинi M. Chk1 frameshift mutations in genetically unstable colorectal and endometrial cancers. **Genes, Chromosomes and Cancer** 1999; 26: 176-180.
269. Furlan D, Bertoni F, Cerutti R, Taborelli M, Pinotti G, Roggero E, Cavalli F, Bonato M, Zucca E, Capella C. Microsatellite instability in gastric MALT lymphomas and in associated other neoplasms. **Annals of Oncology** 1999; 10: 783-788.
270. Bertoni F, Luminari S, Intini D, Carobbio S, Codegioni AM, Spataro V, Neri A. Analysis of *BCL10* gene mutations in ovarian cancer cell lines. **Annals of Oncology** 1999; 10: 1259-1260.
271. Codegioni AM, Bertoni F, Patregnani C, Marinetti E, D'Incalci M, Brogгинi M. Allelic expression of p73 in human ovarian cancers. **Annals of Oncology** 1999; 10: 949-953.

272. Bertoni F, Zucca E, Genini D, Cazzaniga G, Roggero E, Ghielmini M, Cavalli F, Biondi A. Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. **Leukemia and Lymphoma**, 1999; 36: 147-150.
273. Bertoni F, Roggero E, Luscieti P, Pedrinis E, Cavalli F, Zucca E. Clonality assessment in blood of patients with mantle cell lymphoma. **Leukemia and Lymphoma** 1999; 32: 375-379.
274. Bieri S, Roggero E, Zucca E, Bertoni F, Pianca S, Sanna P, Pedrinis E, Bernier J, Cavalli F. Primary mediastinal large B-cell lymphoma (PMCL): the need for prospective clinical trials. **Leukemia and Lymphoma** 1999; 35: 139-46.
275. Codegoni AM, Bertoni F, Colella G, Caspani G, Grassi L, D'Incalci M, Broggin M. Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer. **Oncology Research** 1999, 11: 297-301.
276. Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, Biondi A, Cavalli F. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to MALT lymphoma of the stomach. **New England Journal of Medicine** 1998; 338: 804-810.
277. Zucca E, Bertoni F, Roggero E, Cazzaniga G, Bosshard G, Biondi A, Cavalli F. Autoreactive B-cell clones in marginal-zone B-cell lymphoma (MALT lymphoma) of the stomach. **Leukemia** 1998; 12: 247-249.
278. Baldini L, Blini M, Guffanti A, Fossati V, Colombi M, Bertoni F, La Targia ML, Motta M, Neri A, Bertoni G. Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. **Annals of Oncology** 1998; 9: 779-781.
279. Sanna P, Bertoni F, Zucca E, Roggero E, Passegga Sidler E, Fiori G, Pedrinis E, Mombelli G, Cavalli F. Cardiac involvement in primary extranodal HIV-related lymphoma of the liver: a case report and short review of the literature. **Annals of Haematology** 1998; 77: 75-78.
280. Foa P, Massaro P, Caldiera S, La Targia ML, Iurlo A, Clerici C, Fornier M, Bertoni F, Maiolo AT. Long term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. **European Journal of Haematology** 1998; 60: 273-277.
281. Bertoni F, Sanna P, Zucca E, Roggero E, Cavalli F. Primary extranodal lymphoma of skeletal muscles: a report of four cases and discussion of the literature. **Oncology Reports** 1998; 5: 605-607.
282. Bertoni F, Cazzaniga G, Bosshard G, Roggero E, Barbazza R, De Boni M, Capella C, Pedrinis E, Cavalli F, Biondi A, Zucca E. Immunoglobulin heavy chain D gene rearrangement pattern indicates that the MALT type gastric lymphoma B-cells have undergone an antigen selection process. **British Journal of Haematology** 1997; 97: 830-836.
283. Bertoni F, Bosshard G, Roggero E, Ceresa E, Cavalli F, Zucca E. Clinical relevance of BCL-2(MBR)/J<sub>H</sub> rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. **British Journal of Cancer** 1997; 76: 36-39.
284. Pinotti G, Zucca E, Roggero E, Pascarella A, Bertoni F, Savio A, Savio E, Capella C, Pedrinis E, Saletti PC, Capella C, Morandi E, Santandrea G, Cavalli F. Clinical features, treatment outcome in a series of 93 patients with low-grade gastric MALT lymphoma. **Leukemia and Lymphoma** 1997; 26: 527-537.
285. Sanna P, Bertoni F, Roggero E, Quattropani C, Rusca T, Pedrinis E, Monotti R, Mombelli G, Cavalli F, Zucca E. Angiotropic (intravascular) lymphoma: a case report and short review of the literature. **Tumori** 1997; 83: 772-775.
286. Foa P, Iurlo A, Orazi A, Saglio G, Ribera S, Bertoni F, Caldiera S, Fornier M, Maiolo AT. Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. **Acta Haematologica** 1997; 97: 187-188.
287. Iurlo A, Fornier M, Caldiera S, Bertoni F, Foa P. Palmar-plantar erythrodysesthesia syndrome due to 5-fluorouracil therapy - an underestimated toxic event? **Acta Oncologica** 1997; 36: 653-654
288. Zucca E, Bertoni F, Bosshard G, Roggero E, Ceresa E, Sanna P, Pedrinis E, Cavalli F. Clinical significance of bcl-2 (mbr) /J<sub>H</sub> rearrangement in the peripheral blood of patients with diffuse, large B-cell lymphomas. **Annals of Oncology** 1996; 7: 1023-1027.
289. Foa P, Iurlo A, Ribera S, Da Milano I, Caldiera S, Fornier M, Bertoni F, Maiolo AT. Chronic myeloid leukemia treated with busulfan: relationship between total amount of drug required during the first year of treatment and duration of chronic phase. **Oncology Reports** 1996; 3: 1067-1069.
290. Foa P, Pomati M, Ribera S, Caldiera S, Bertoni F, Fornier M, Maiolo AT. Fluorescence *in situ* hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interferon alpha therapy. **Oncology Reports** 1996; 3: 847-849.

## B) REVIEWS AND EDITORIALS

1. Laurent C\* & Bertoni F\*. The Biology of Marginal Zone Lymphoma Subtypes: Challenge and Relevance of Classification. **Blood** 2025; *in press*. (\*, co- corresponding authors).
2. De Ramon Ortiz C, Wang S, Stathis A, Bertoni F, Zenz T, Simonetta F. How to integrate CD19 specific CAR T cells with other CD19 targeting agents in diffuse large B cell lymphoma? **Hematological Oncology** 2024 Jan;42(1): e3237. doi: 10.1002/hon.3237. Epub 2023 Nov 8.
3. Barreca M, Bertoni F, Barraja P. New strategies to hit hematological cancers. **Eur J Med Chem** 2024 Apr 15;270:116350. doi: 10.1016/j.ejmech.2024.116350. Epub 2024 Mar 20
4. Tarantelli C, Bertoni F. Bimiralisib **Drugs of the Future** 2023, 48(3): 155-164. doi:10.1358/dof.2023.48.3.3509749.
5. Zucca E, Rossi D, Bertoni F. Marginal zone lymphomas. **Hematological Oncology** 2023 Jun;41 Suppl 1:88-91. doi: 10.1002/hon.3152.
6. Barreca M, Lang N, Tarantelli C, Spriano F, Barraja P, Bertoni F. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences. **Exploration of Targeted Anti-tumor Therapy** 2022;3(6):763-794. doi: 10.37349/etat.2022.00112. Epub 2022 Dec 26.
7. Griguolo G<sup>^</sup>, Zorzi MF<sup>^</sup>, Piroso MC, Treglia G, Bertoni F, Kuruvilla J, Zucca E, Stathis A. A systematic review of contemporary phase I trials in patients with lymphoma. **Critical Reviews in Oncology / Hematology** 2022 Dec;180:103860. doi: 10.1016/j.critrevonc.2022.103860. Epub 2022 Oct 18. (<sup>^</sup>, equally contributed).
8. Tarantelli C, Bertoni F. United we stand: double targeting of CD79B and CD20 in diffuse large B cell lymphoma. **British Journal of Haematology** 2022 Oct;199(2):169-170.
9. Vannata B, Piroso MC, Bertoni F, Rossi D, Zucca E. Bacterial infection-driven lymphomagenesis. **Current Opinion in Oncology** 2022 Sep 1;34(5):454-463.

10. Bertoni F, Rapposelli S. Editorial: New Insights into The Mechanisms of Resistance to Anti-Cancer Drugs. **Frontiers in Oncology, section Pharmacology of Anti-Cancer Drugs** 2022 Jul 26;12:990144.
11. Rossi D, Bertoni F, Zucca E. Marginal zone lymphomas. **New England Journal of Medicine** 2022; 386: 568-81.
12. Simonetta F, Bertoni F. Epigenetic signature in CD19-CAR T cells predicts clinical outcome. **Trends in Cancer** 2022; 8 (2): 81-82.
13. Napoli S, Munz N, Guidetti F, Bertoni F. Enhancer RNAs (eRNAs) in cancer: the jacks of all trades. **Cancers** 2022 Apr 14;14(8):1978.
14. Barreca M, Spanò V, Raimondi MV, Bivacqua R, Giuffrida S, Montalbano A, Cavalli A, Bertoni F, Barraja P. GPCR inhibition in treating lymphoma. **ACS Medicinal Chemistry Letters** 2022, 13, 3, 358–364.
15. Bertoni F\*, Montesinos-Rongen M\*. Primary diffuse large B-cell Lymphoma of the central nervous system: molecular and biological features of neoplastic cells. **Annals of Lymphoma** 2022;6:1 | <https://dx.doi.org/10.21037/aol-21-3> (\*, co-corresponding authors).
16. Tarantelli C, Argnani L, Zinzani PL, Bertoni F. PI3K $\delta$  inhibitors as immunomodulatory agents for the treatment of lymphoma patients. **Cancers** 2021 Nov 4;13(21):5535.
17. El Tekle G, Bernasocchi T, Unni AM, Bertoni F, Rossi D, Rubin D, Theurillat JP. Co-occurrence & Mutual Exclusivity: What Cross-Cancer Mutations Patterns Can Tell Us. **Trend in Cancer** 2021 Sep;7(9):823-836.
18. Barreca M, Spanò V, Raimondi MV, Tarantelli C, Spriano F, Bertoni F, Barraja P, Montalbano A. Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. **European Journal of Medicinal Chemistry Reports** 2021; 1: 100004. <https://doi.org/10.1016/j.ejmcr.2021.100004>.
19. Lue JK\*, O'Connor OA, Bertoni F\*. Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond. **Annals of Lymphoma** 2020; 4: 7 doi: 10.21037/aol-20-20 (\*, co-corresponding authors).
20. Chiappa M<sup>^</sup>, Guffanti F<sup>^</sup>, Bertoni F, Colombo I, Damia G. Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer. **Drug Resistance Updates** 2021 Mar;55: 100744. doi: 10.1016/j.drug.2021.100744. Epub 2021 Jan 16. (<sup>^</sup>, equally contributed)
21. Cascione L, Aresu L, Baudis M, Bertoni F. DNA copy number changes in diffuse large B-cell lymphomas. **Frontiers in Oncology** 2020 Dec 2;10: 584095. doi: 10.3389/fonc.2020.584095
22. Rotter A, Barbier M, Bertoni F, Bones AM, Cancela ML, Carlsson J, Carvalho MF, Ceglowska M, Chirivella-Martorell J, Dalay MC, Cueto M, Dailianis T, Deniz I, Díaz-Marrero AR, Drakulovic D, Dubnika A, Edwards C, Einarsson H, Erdoğan A, Eroldoğan OT, Ezra D, Fazi S, FitzGerald RJ, Gargan LM, Gaudêncio SP, Udovič MG, DeNardis NI, Jónsdóttir R, Kataržytė M, Klun K, Kotta J, Ktari L, Zrinka Ljubešić Z, Bilela LL, Mandalakis M, Massa-Gallucci A, Matijošytė I, Mazur-Marzec H, Mehiri M, Nielsen SL, Novoveská L, Overlingė D, Perale G, Ramasamy P, Rebours C, Reinsch T, Reyes F, Rinkevich B, Robbens J, Röttinger E, Rudovica V, Sabotič J, Safarik I, Talve S, Tasdemir D, Schneider XT, Thomas OP, Anna Toruńska-Sitarz A, Varese GC, Vasquez MI. The essentials of marine biotechnology. **Frontiers in Marine Science** 16 March 2021. <https://doi.org/10.3389/fmars.2021.629629>.
23. Spriano F, Stathis A, Bertoni F. Targeting BET bromodomain proteins in cancer: the example of lymphomas. **Pharmacology & Therapeutics** 2020 Nov;215:107631. doi: 10.1016/j.pharmthera.2020.107631.
24. Barreca M, Spanò V, Montalbano A, Cueto M, Díaz Marrero AR, Deniz I, Erdoğan A, Lukić Bilela L, Moulin C, Taffin-de-Givenchy E, Spriano F, Perale G, Mehiri M, Rotter A, Thomas OP, Barraja P, Gaudêncio SP\*, Bertoni F\*. Marine anticancer agents: an overview with a particular focus on their chemical classes. **Marine Drugs** 2020, 18, 619. <https://doi.org/10.3390/md18120619> (\*, co-corresponding authors).
25. Barreca M, Stathis A, Barraja P, Bertoni F. An overview on anti-tubulin agents for the treatment of lymphoma patients. **Pharmacology & Therapeutics** 2020 Jul;211:107552. <https://doi.org/10.1016/j.pharmthera.2020.107552>.
26. Carrassa L, Colombo I, Damia G\*, Bertoni F\*. Targeting the DNA damage response for patients with lymphoma: preclinical and clinical evidences. **Cancer Treatment Reviews** 2020 Nov;90:102090. doi: 10.1016/j.ctrv.2020.102090. (\*, co-corresponding authors).
27. Bertoni F, Rossi D, Raderer M, Zucca E. Marginal zone lymphomas. **The Cancer Journal** Jul/Aug 2020;26(4):336-347. doi: 10.1097/PPO.0000000000000463.
28. Tarantelli C, Lupia A, Stathis A, Bertoni F. Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma? **International Journal of Molecular Sciences** 2020: Feb 5;21(3):1060. doi: 10.3390/ijms21031060.
29. Rotter A\*, Bacu A, Barbier M, Bertoni F, Bones A, Cancela ML, Carlsson J, Carvalho MF, Ceglowska M, Dalay MC, Dailianis T, Deniz I, Drakulovic D, Dubnika A, Einarsson H, Erdoğan A, Eroldoğan OT, Ezra D, Fazi S, FitzGerald RJ, Gargan LM, Gaudêncio SP, DeNardis NI, Joksimovic D, Kataržytė M, Kotta J, Mandalakis M, Matijošytė I, Mazur-Marzec H, Massa-Gallucci A, M, Nielsen SL, Novoveská L, Overlingė D, Portman ME, Pycr K, Rebours C, Reinsch T, Reyes F, Rinkevich B, Robbens J, Rudovica V, Sabotič J, Safarik I, Talve S, Tasdemir D, Schneider XT, Thomas OP, Toruńska-Sitarz A, Varese GC, Vasquez MI. A new network for the advancement of marine biotechnology in Europe and beyond. **Frontiers in Marine Science** 2020; 7: Article 278. <https://doi.org/10.3389/fmars.2020.00278>.
30. Bertoni F & Stathis A. BET inhibitors for lymphoid malignancies. **Current Opinion in Hematology** 2019 Jul;26(4):273-280. doi: 10.1097/MOH.0000000000000519.
31. Mondello P, Mian M, Bertoni F. Primary central nervous system lymphoma: novel precision therapies. **Critical Reviews in Oncology/Hematology** 2019 Sep;141:139-145.
32. Stathis A & Bertoni F. BET proteins as targets for anti-cancer treatment. **Cancer Discovery** 2018 Jan;8(1):24-36.
33. Minotti G, Han H, Cattani V, Egorov A, Bertoni F. Pixantrone: novel mode of action and clinical readouts. **Expert Review of Hematology** 2018 Jul; 11(7): 587-598.
34. Paduano F\*, Gaudio E\*, Mensah AA, Pinton S, Bertoni F, Trapasso F. T-Cell Leukemia/Lymphoma 1 (TCL1): an oncogene regulating multiple signaling pathways. **Frontiers in Oncology** 2018 Aug 13; 8: 317. (\*, equally contributed).
35. Bertoni F\*, Rossi D\* & Zucca E. Recent advances in understanding the biology of marginal zone lymphoma. **F1000Research** 2018, 7(F1000 Faculty Rev):406 (doi: 10.12688/f1000research.13826.1). (\*, equally contributed).
36. Bertoni F. Let's give BACH2 a breath of fresh air. **Blood** 2017 Aug 10; 130(6): 696-697.
37. Bertoni F & Stathis A. Staining the target: CD37 expression in lymphomas. **Blood** 2016 Dec 29;128(26):3022-3023.
38. Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. **Blood** 2016 Apr 28;127(17):2082-92.
39. Arribas AJ, Bertoni F. Methylation patterns in marginal zone lymphoma. **Best Practice & Research Clinical Haematology**

- 2016; 30(1): 24-31.
40. Pizzi M, Boi M, Bertoni F, & Inghirami G. Emerging therapies provide new opportunities to reshape the multifaceted interactions between immune system and lymphoma cells. **Leukemia** 2016 Sep;30(9):1805-1815.
  41. Cogliatti S, Bargetzi M, Bertoni F, Hitz F, Lohri A, Mey U, Papachristofilou A, Taverna C, Zucca E & Renner C. Diagnosis and treatment of marginal zone lymphoma. **Swiss Medical Weekly** 2016;146 (SUPPL 216): 1S-12S.
  42. Testoni M, Young KH, Zucca E, Bertoni F. Genetic lesions in diffuse large B-cell lymphoma. **Annals of Oncology** 2015 26 (6): 1069-1080.
  43. Boi M, Zucca E, Inghirami G, Bertoni F. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. **British Journal of Haematology** 2015 Mar;168(6):771-83.
  44. Testoni M, Chung EY, Priebe V, & Bertoni F. The transcription factor ETS1 in lymphomas: friend or foe? **Leukemia and Lymphoma** 2015 Jan 14:1-6.
  45. Zucca E, Bertoni F, Vannata B, Cavalli F. Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-Cell Lymphomas. **Clinical Cancer Research** 2014; 20(20): 5207-5216.
  46. Boi M, Zucca E, Inghirami G, & Bertoni F. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. **Leukemia and Lymphoma** 2014 Oct 7:1-6.
  47. Zucca E, Stathis A, & Bertoni F. How An Expert Approaches It: The Management of Nongastric MALT Lymphomas. **Oncology** 2014; 28 (1): 86-93.
  48. Thieblemont C\*, Bertoni F\*, Copie-Bergman C, Ferreri A, & Ponzoni M. Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT –type. **Seminars in Cancer Biology** 2014 Feb;24:33-42. \*, equally contributed.
  49. Zucca E, Bertoni F. Toward new treatments for mantle-cell lymphoma ?. **New England Journal of Medicine** 2013; 369(6): 571-572.
  50. Tabbo' F, Ponzoni M, Rabadan R, Bertoni F, Inghirami G. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. **Current Opinion in Hematology** 2013 Jul;20(4):374-381.
  51. Lobetti-Bodoni C, Bertoni F, Stussi G, Cavalli F, Zucca E. The changing paradigm of chronic lymphocytic leukemia management. **Eur J Intern Med.** 2013 Jul;24(5):401-10.
  52. Boi M, Stathis A, Zucca E, Inghirami G, Bertoni F. Nodal Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T- and NK-cells. **Cancer Science** 2012; 103(8): 1397-404.
  53. Thieblemont C, Davi F, Noguera ME, Briere J, Bertoni F, Zucca E, Traverse-Glehen A, Berger S, Salles G, Coiffier B. Splenic Marginal Zone B Cell Lymphoma. **Oncology (Williston Park)** 2012 Feb;26(2):194-202.
  54. Traverse-Glehen A, Bertoni F, Thieblemont C, Zucca E, Coiffier B, Berger S, Salles G. Nodal Marginal Zone B Cell Lymphoma: A diagnosis and therapeutic dilemma. Current knowledge and future directions. **Oncology (Williston Park)** 2012; 26(1): 92-99.
  55. Bertoni F, Coiffier B, Salles G, Stathis A, Traverse-Glehen A, Thieblemont C, Zucca E. MALT Lymphomas: Pathogenesis can drive treatment. **Oncology** 2011; 25: 25(12): 1134-1142.
  56. Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G and the European T-Cell Lymphoma Study Group. Anaplastic lymphoma kinase (ALK) in human cancer. **Journal of Molecular Endocrinology** 2011; 47 (1): R11-23.
  57. Dal Bo M, Dal Giudice I, Bomben R, Capello D, Bertoni F, Forconi F, Laurenti L, Rossi D, Zucchetto A, Pozzato G, Marasca R, Efremov D, Guarini A, Del Poeta G, Foa' R, Gaidano G, Gattei V. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukemia: the growing saga of the IGHV3 subgroup gene usage. **British Journal of Haematology** 2011 Apr; 153(1): 3-14.
  58. Stathis A, Bertoni F, Zucca E. Treatment of gastric marginal zone lymphoma of MALT type. **Expert Opinion On Pharmacotherapy** 2010; 11(13): 2141-2152.
  59. Motta M, Gregorini A, Bertoni F, Uhr M, Zucca E. Nuove prospettive per pazienti con leucemia linfatica cronica. **Tribuna Medica Ticinese** 2010; 75: 5-12.
  60. Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bomben R, Marasca R, Deaglio S, Laurenti L, Efremov DG, Gaidano G, Del Poeta G, Gattei V. Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. **Journal of Translational Medicine**: 2009 Aug 28; 7: 76.
  61. Zucca E, Bertoni F, Stathis A, Cavalli F. Marginal Zone Lymphomas. **Hematology/Oncology Clinics of North America**: 2008; 22(5):883-901.
  62. Bertoni F. Hematological Oncology: further ahead. **Hematological Oncology** 2008; 26(1): 1-2.
  63. Ferreri AJM, Dolcetti R, Du M-Q, Doglioni C, Resti AG, Politi LS, De Conciliis C8, Radford J, Bertoni F, Zucca E, Cavalli F, Ponzoni M. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. **Annals of Oncology**: 2008; 19(5): 835-846.
  64. Bertoni F, Forconi F, Rossi D, Gattei V, Gaidano G, Zucca E. The Molecular Genetics of Chronic Lymphocytic Leukemia. **Schweizer Krebs-Bulletin** 2008; 28(3): 189-193.
  65. Bertoni F, Ponzoni M. The Cellular Origin of Mantle Cell Lymphoma. **The International Journal of Biochemistry, Cell Biology** 2007; 39: 1747-1753.
  66. Zucca E, Bertoni F. Bendamustine in lymphomas: more to combine? **Leukemia And Lymphoma** 2007; 48: 1264-1266.
  67. Zucca E, Bertoni F. Chlamydia or not Chlamydia, that is the question. Which is the microorganism associated with MALT lymphomas of the ocular adnexa? **Journal of the National Cancer Institute** 2006; 98: 1348-1349.
  68. Bertoni F, Zucca E. Delving deeper into MALT lymphoma biology. **Journal of Clinical Investigation** 2006; 116: 22-26.
  69. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. **Hematological Oncology** 2006; 24: 22-27.
  70. Bertoni F, Zucca E. State-of-the-Art Therapeutics: Marginal-Zone Lymphoma. **Journal of Clinical Oncology** 2005; 23: 6415-6420.
  71. Zucca E, Bertoni F. Another piece of the MALT lymphomas jigsaw. **Journal of Clinical Oncology** 2005; 23: 4832-4.
  72. Bertoni F, Zucca E, Cavalli F. Mantle cell lymphoma. **Current Opinion in Hematology** 2004; 11: 411-418.
  73. Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. **British Journal of Haematology** 2004; 124: 130-140.
  74. Zucca E, Bertoni F, Cavalli F. Pathogenesis and treatment of extranodal lymphomas: the fascinating model of mucosa-associated lymphoid tissue lymphoma. **Haematologica** 2003; 88 (8): 841-844.

75. Bertoni F, Ghielmini M, Cavalli F, Cotter FE, Zucca E. Mantle cell lymphoma: new treatments targeted to the biology. **Clinical Lymphoma** 2002; 3: 90-96.
76. Bertoni F, Cavalli F, Cotter FE, Zucca E. Genetic alterations underlying the pathogenesis of MALT lymphoma. **The Hematology Journal** 2002; 3: 10-13.
77. Zucca E, Bertoni F, Cavalli F. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue type. **Haematologica** 2002; 87 (suppl. 1 to 11): 33-36.
78. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. **Blood** 2000; 96: 410-419.
79. Bertoni F, Cotter FE, Zucca E. Molecular genetics of extranodal marginal zone (MALT-type) B-cell lymphoma. **Leukemia and Lymphoma** 1999; 35: 57-68.
80. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. **Annals of Oncology** 1999; 10(9): 1023-1033.
81. Zucca E, Bertoni F, Roggero E, Cavalli F. Management of rare forms of lymphomas. **Current Opinion in Oncology** 1998; 10: 377-384.
82. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. **Annals of Oncology** 1997; 8: 727-737.
83. Iurlo A, Bertoni F, Foa P. La verità al malato oncologico: perchè, come. **La Ca' Granda** 1995; 36 (3-4): 41-42.

### C) BOOK CHAPTERS

1. Arribas JA, Bertoni F. Molecular biology of lymphomas. In: Montoto S, Dreyling M, Ballova V (eds). **Lymphoma - Essentials for Clinicians, 3<sup>rd</sup> edition**. ESMO Press, 2024: 85-88.
2. Bertoni F, Zucca E. Extranodal marginal zone lymphoma of MALT type. In: Montoto S, Dreyling M, Ballova V (eds). **Lymphoma - Essentials for Clinicians, 3<sup>rd</sup> edition**. ESMO Press, 2024: 61-66.
3. Tarantelli C, Bertoni F. In: O'Connor OA, Ansell SM, Seymour JF (eds). Targeting the Cell Cycle and Cyclin-dependent Kinases. **Precision Cancer Therapies, Volume 1 - Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice**. John Wiley & Sons, 2023: 444-456.
4. Aresu L, Comazzi S, Marconato L, Bertoni F. B-cell tumors. In: Brooks MB, Harr KE, Seelig DM, Wardrop KJ, Weiss DJ (eds.) **Schalm's Veterinary Hematology**, 7th Edition. John Wiley and Sons, Inc., 2022: 570-587.
5. Bertoni F. Molecular biology of lymphomas. In: Ghielmini M, Montoto S (eds). **Lymphoma - Essentials for Clinicians, 2<sup>nd</sup> edition**. ESMO Press, 2015: 81-84.
6. Bertoni F, Zucca E. Extranodal marginal zone lymphoma of MALT type. In: Ghielmini M, Montoto S (eds). **Lymphoma - Essentials for Clinicians, 2<sup>nd</sup> edition**. ESMO Press, 2015: 55-60.
7. Bertoni F, Forconi F, Dal-Bo M, Zucchetto A, Bomben R, Del Poeta G, Gattei V. Molecular Pathology - B-cell chronic lymphocytic leukemia. In: Gelmann E, Sawyers C, Rauscher F III (eds). **"Molecular Oncology: Causes of Cancer and Targets for Treatment"**, Cambridge University Press, 2014: 786-792.
8. Zucca E, Bertoni F. MALT and Other Marginal Zone Lymphomas. In: Marcus R., Sweetenham J.W., Williams M.E. (eds). **"Lymphoma: Pathology, Diagnosis and Treatment (2<sup>nd</sup> ed.)"**, Cambridge University Press, 2014: 104-120.
9. Bertoni F, Li Z.M., Zucca E. Where do we stand in the genomics of lymphomas? In: Pfeffer U. (ed) **Cancer Genomics: Molecular Classification, Prognosis and Response Prediction**. Springer-Verlag, 2013: 495-541.
10. Zucca E, Bertoni F, Cavalli F. Extranodal marginal zone lymphoma of MALT type. In: Younes A., Coiffier B (eds) **Lymphoma: Diagnosis and Treatment**. Humana Press, 2013: 111-126.
11. Bertoni F. Pathologic diagnosis: molecular genetics. In: Carbone A., Younes A. (eds) **Non-Hodgkin Lymphomas: Advanced Diagnostics, Personalized Therapies**. Future Science Group, 2013: 56-81.
12. Stathis A, Bertoni F, Zucca E, Cavalli F. MALT lymphoma: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. In: Carbone A., Younes A. (eds) **Non-Hodgkin Lymphomas: Advanced Diagnostics, Personalized Therapies**. Future Science Group, 2013: 250-262.
13. Rinaldi A, Capello D, Zucca E, Gaidano G, Bertoni F. Genome Wide DNA-Profiling of HIV-Related B-Cell Lymphomas. In: Banerjee, Diponkar; Shah, Sohrab P. (eds.) **Array Comparative Genomic Hybridization: Protocols and Applications**. Springer: Protocols and Applications Series: Methods in Molecular Biology, 2013; Vol. 973: 213-236.
14. Bertoni F, Zucca E. Extranodal marginal zone lymphoma of MALT type. In: Ghielmini M, Montoto S. (eds) **Lymphoma - Essentials for Clinicians**. ESMO, 2012: 55-60.
15. Zucca E, Bertoni F, Thieblemont C. Marginal zone B-cell lymphomas. In: López-Guillermo A, Salles G (eds). **"International Hematology Updates - Lymphoma in the XXI Century"**, Barcelona, Permanyer Publications, 2010: 73-99.
16. Zucca E, Bertoni F, Yahalom J, Isaacson PG. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla Favera R (eds). **"Non-Hodgkin Lymphomas, 2nd edition"**, Philadelphia, Wolters Kluwer / Lippincott Williams, Wilkins, 2010: 232-253.
17. Gospodarowicz M, Bertoni F, Zucca E. Unique aspects of primary extranodal lymphomas. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla Favera R (eds). **"Non-Hodgkin Lymphomas, 2nd edition"**, Philadelphia, Wolters Kluwer / Lippincott Williams, Wilkins, 2010: 540-556.
18. Rancoita PMV, Hutter M, Bertoni F, Kwee I. Bayesian joint estimation of CN and LOH aberrations. **Lecture Notes in Computer Science**, 2009: 5518: 1109-1117.
19. Bertoni F, Gascoyne RD. Pathobiology and molecular basis of MALT lymphoma. In: Cavalli F, Stein H, Zucca E (eds). **"Extranodal Lymphomas - Pathology and Management"**, London, Informa Healthcare, 2008: 67-77.
20. Zucca E, Bertoni F. MALT Lymphoma and Other Marginal Zone Lymphomas. In: Marcus R., Sweetenham J.W., Williams M.E. (eds). **"Lymphoma: Pathology, Diagnosis and Treatment"**, Cambridge University Press, 2007: 126-140.
21. Zucca E, Bertoni F, Cavalli F. Marginal zone B cell lymphomas. In: Canellos G, Lister TA, Young B (eds). **The Lymphomas, 2<sup>nd</sup> edition**. W.B. Saunders 2006: 381-396.
22. Bertoni F, Cotter FE, Du MQ. MALT lymphoma: genetics and biology. In: Bertoni F, Zucca E (eds). **MALT lymphomas**. Georgetown, TX, USA: Kluwer Academics / Landes Bioscience 2004: 46-59.
23. Cotter FE, Bertoni F. The *BCL6* story. In Cavalli F, Armitage JO, Longo DL (eds): **Annual of Lymphoid Malignancies**. London: Martin Dunitz 2001; 21-29.
24. Zucca E, Conconi A, Bertoni F, Cavalli F. Linfoma gastrico di tipo MALT. Ruolo dell'infezione da *Helicobacter pylori*. In Bianchi Porro G, Maconi G, Parente F (eds): **L'infezione da Helicobacter pylori: aggiornamento continuo**. Vol. 2. Verona: Libreria

**D) EDITED BOOKS**

Bertoni F, Zucca E (eds). **MALT lymphomas**. Georgetown, TX, USA: Kluwer Academics / Landes Bioscience 2004: 1-133.

**E) PEER-REVIEWED CONFERENCE PAPERS**

1. Pontali G<sup>^</sup>, Cascione L<sup>^</sup>, Arribas AJ, Rinaldi A, Bertoni F, Giugno R. A Reliable Method to Remove Batch Effects Maintaining Group Differences in Lymphoma Methylation Case Study. In: Rojas I., Valenzuela O., Rojas F., Ortuño F. (eds) Bioinformatics and Biomedical Engineering. IWBBIO 2019. Lecture Notes in Computer Science, 2019, vol 11466. Springer, Cham.

**F) PRE-PRINTS**

1. Arribas AJ, Civanelli E, Scalise C, Cascione L, Rinaldi A, Rossi D, Emanuele Zucca E, Carosella L, Raniolo S, Limongelli V, Bertoni F. Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclax. **BioRxiv** 2025 November 26; doi: <https://doi.org/10.1101/2025.11.24.690186>.
2. Tarantelli C, Civanelli E, Spriano F, Risi G, Cascione L, Kaufmann G, Bertoni F. Characterization of lymphoma models for the surface ROR1 expression. **BioRxiv** 2025 November 19; doi: <https://doi.org/10.1101/2025.11.19.684505>.
3. Spriano F, Cascione L, Tarantelli C, Sartori G, Arribas AJ, Velasova A, Napoli S, Havranek O, Toretsky JA, Bertoni F. Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma. **BioRxiv** 2025 September 20; doi: <https://doi.org/10.1101/2025.09.18.675797>.
4. Spriano F, Arribas AJ, Zhang F, Mangoni ML, Buonocore F, Bertoni F. Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies. **BioRxiv** 2025 September 17; doi: <https://doi.org/10.1101/2025.09.13.674604>
5. Barnabei L, Arribas AJ, Cascione L, Guidetti F, Spriano F, Tarantelli C, Di Cristofano S, Raniolo S, Rinaldi A, Stathis A, Rossi D, Zucca E, Limongelli V, Zimmermann J, Bertoni F. Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models. **BioRxiv** 2025 July 15. <https://doi.org/10.1101/2025.07.10.664047>
6. Arribas AJ, Guidetti F, Cannas E, Cascione L, Napoli S, Sartori G, Fuzio F, Pesenti E, Tarantelli C, Spriano F, Zucchetto A, Rossi FM, Bruscazzin A, Rinaldi A, Castro de Moura M, Jovic S, Raimondi A, Bordone Pittau R, Terzi di Bergamo L, Ye X, Stathis A, Ben-David Y, Pan-Hammarström Q, Simonetta F, Stussi G, Zucca E, Gattei V, Brown JR, Esteller M, Rossi D, Bertoni F. IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas. **BioRxiv** 2025 May 10. <https://doi.org/10.1101/2025.05.07.652612>.
7. Cascione L, Guidetti F, Ramnarayanan S, Rinaldi A, Spriano, Zadro A, Tarantelli C, Munz N, Arribas AJ, Johnson R, Bertoni F, Napoli A\*. The Enhancer lncRNA LOC730338 Drives Ibrutinib Resistance and Tumor Immune Evasion in Lymphoma via ADAR2-Dependent Alternative Transcription. **BioRxiv** 2024 December 12. <https://doi.org/10.1101/2024.12.10.627805>. (\*, co-corresponding authors).
8. Aresu L, Mazzone E, Marconato L, Fanelli A, Cascione L, Bertoni F. The Genetic Landscape of Canine Tumors: Insights from the Canine Cancer Genome Atlas (CCGA). **Research Square** 2024 September 19 <https://doi.org/10.21203/rs.3.rs-5025541/v1>
9. Spriano F\*, Cascione L, Sgrignai J, Bendik N, Napoli S, Sartori G, Cannas E, Gong T, Arribas AJ, Pizzi M, Rossi D, Robbiani DF, Cavalli A, Bertoni F\*. Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity. **BioRxiv** 2024 January 18. <https://doi.org/10.1101/2024.01.17.576027>. (\*, co-corresponding authors).
10. Akhmedov M, Galbusera L, Montemanni R, Bertoni F, Kwee I. A prize-collecting Steiner tree application for signature selection to stratify diffuse large B-cell lymphoma subtypes. **BioRxiv** 2018; 272294; doi: <https://doi.org/10.1101/272294>
11. Akhmedov M, Arribas A, Montemanni R, Bertoni F, Kwee I. OmicsNet: Integration of Multi-Omics Data using Path Analysis in Multilayer Networks. **BioRxiv** 2017; 238766; doi: <https://doi.org/10.1101/238766>
12. Kwee I, Rinaldi A, de Campos C, Bertoni F. Fast and Robust Segmentation of Copy Number Profiles Using Multi-Scale Edge Detection. **BioRxiv** 2016 056705; doi: <http://dx.doi.org/10.1101/056705>.

**G) SELECTED ABSTRACTS**

1. Spriano F, Sartori G, Tarantelli C, Cascione L, Napoli S, Mehli F, Spohn G, Bertoni F. Abstract 7332: Investigating genes and pathways determining sensitivity or resistance to anti-L1cam ADCs in lymphomas. **Cancer Research** 2025; 85(8\_Supplement\_1):7332. (AACR 2025)
2. Arribas AJ, Choi B, Civanelli E, Cannas E, Scalise C, Hong S, Lee H, Bertoni F. Abstract 1878: Profiling protein-protein interactions to predict sensitivity to drugs targeting BCL2 family members in lymphoma models. **Cancer Research** 2025; 85(8\_Supplement\_1):1878. (AACR 2025)
3. Arribas AJ, Cannas E, Rossi D, Stathis A, Heiser D, Bertoni F. Abstract 5410: CDK9 pharmacological inhibition has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitors. **Cancer Research** 2025; 85(8\_Supplement\_1):5410. (AACR 2025)
4. Arribas AJ, Civanelli E, Scalise C, Cascione L, Rinaldi A, Rossi D, Zucca E, Bertoni F. Abstract 410: The BTK degrader BGB-16673 shows anti-tumor activity in marginal zone lymphoma models. **Cancer Research** 2025; 85(8\_Supplement\_1):410. (AACR 2025)
5. Spriano F, Arribas AJ, Zhang F, Mangoni ML, Buonocore F, Bertoni F. Abstract 612: Antimicrobial peptides with antitumor activity against marginal zone lymphoma cell lines resistant to BTK, PI3K, and BCL2 inhibitors. **Cancer Research** 2025; 85(8\_Supplement\_1):612. (AACR 2025)
6. Spriano F, Arribas AJ, Bendik N, Girão M, Ribeiro I, Carvalho MF, Bertoni F, Leão P. Abstract 611: Actinobacteria from macroalgae as a source of new anti-lymphoma compounds. **Cancer Research** 2025; 85(8\_Supplement\_1):611. (AACR 2025)
7. Arribas AJ, Cannas E, Pileri S, Rossi D, Heiser D, Bertoni F. Abstract 411: Selective degradation of SMARCA2 and dual degradation of SMARCA2 and SMARCA4 has strong antitumor activity in marginal zone lymphoma (MZL). **Cancer Research** 2025; 85(8\_Supplement\_1):411. (AACR 2025)

8. Tarantelli C, Sartori G, Spriano F, Civanelli E, Cascione L, Rinaldi A, Niewola-Staszewska K, Lahn M, Napoli S, Di Conza G, Bertoni F. Loss-of-function and gain-of-function genetic screens identify potential biomarkers and combination partners for the highly selective allosteric PI3K $\delta$  inhibitor rognolisib (IOA-244). **European Journal of Cancer** 2024; 211S1: S16-S16.
9. Mensah AA, Noce B, Spriano F, Tarantelli C, Arribas AJ, Mai A, Sepporta MV, Bertoni F. Identification of inhibitors of BCL2 family members and glucose metabolism as effective combination partners of belinostat in T-cell lymphoma (TCL) cell lines. **European Journal of Cancer** 2024; 211S1: S95-S96.
10. Sartori G, Priebe V, Cascione L, Chung EYL, Favre-Juilland M, Napoli S, Arribas AJ, Giuffrida S, Rinaldi A, Thome-Miazza M Bertoni F. The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle regulation, immune evasion and small nucleolar RNA processing to sustain the survival of DLBCL cells. **Blood Cancer Discov** 2024; 5 (3\_Supplement): PO-015 (AACR-ICML 2024).
11. Napoli S, Arribas AJ, Cannas E, Fuzio F, Cascione L, Rinaldi A, Zucca E, Alimonti A, Stathis A, Bertoni F. CRISPR/Cas9 screening identifies genes affecting the sensitivity to the copanlisib/venetoclax combination in lymphoma cells. **Cancer Research** 2024; 84 (6\_Supplement): 5836. (AACR 2024)
12. Arribas AJ, Cascione L, Cannas E, Bellerjeau H, Fuzio F, Noguera A, Rinaldi A, Esteller M, Zucca E, Alimonti A, Rossi D, Stathis A, Bertoni F. Novel marginal zone lymphoma models of resistance to the dual inhibition of PI3K and BCL2. **Cancer Research** 2024; 84 (6\_Supplement): 534. (AACR 2024)
13. Chung EYL, Spriano F, Napoli S, Sartori G, Cascione L, Bertoni F. The small nucleolar RNA SNORD46 and SNORD72 have tumor suppressor activity in diffuse large B cell lymphoma. **Cancer Research** 2024; 84 (6\_Supplement): 463. (AACR 2024)
14. Spriano F, Sartori G, Aresu L, Cascione L, Civanelli E, Mensah AA, Tarantelli C, Pileri S, Mehli F, Spohn G, Bertoni F. L1CAM targeting antibody-based therapy as a novel approach for L1CAM positive lymphomas. **Molecular Cancer Therapeutics** 2023 22 (12\_Supplement): C112.
15. Sartori G, Spriano F, Cascione L, Tarantelli C, Arribas AJ, Aresu L, Rossi D, Damia G, Brogginini M, Bertoni F. The in vitro anti-tumor activity of the multi-kinase inhibitor nemtabrutinib (ARQ-531, MK-1026) is seen across multiple B-cell lymphoma subtypes, only partially overlapping with what achieved by single BTK inhibition. **Molecular Cancer Therapeutics** 2023; 22 (12\_Supplement): B170. (AACR-NCI-EORTC 2023).
16. Mensah AA, Alessandro Ghiringhelli A, Sartori G, Spriano F, Tarantelli C, Cascione L, Rinaldi A, Arribas AA, Bellarosa D, Binaschi M, Bertoni F. Abstract C144: MEN1703/SEL24, a potent PIM inhibitor, demonstrates promising anti-tumour activity in activated B cell like diffuse large B cell lymphoma, mantle cell lymphoma and marginal zone lymphoma cells. **Molecular Cancer Therapeutics** 2023; 22 (12\_Supplement): C144 (AACR-NCI-EORTC 2023).
17. Barnabei L, Arribas AJ, Cascione L, Guidetti F, Spriano F, Tarantelli C, Rinaldi A, Stathis A, Rossi D, Zucca E, Zimmermann J, Bertoni F. Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B cell lymphoma models. **Cancer Research** 2023 ; 83 (7\_Supplement): 492. (AACR 2023).
18. Bertoni F, Tarantelli C, Spriano F, Cascione L, Civanelli E, Cannas E, Mensah AA, Arribas AJ, Napoli S, Rinaldi A, Stathis A, Niewola K, Di Conza G, Lahn M, Santoro A, Carlo-Stella C. 53P - Characterization of the non-ATP competitive PI3K $\delta$  inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation. **ESMO Open** 2023, 8 (1 S2), 100911. <https://doi.org/10.1016/j.esmoop.2023.100911> (ESMO TAT 2023).
19. Arribas A, Vultaggio S, Andronache A, Robusto M, Fancelli D, Cannas E, Spriano F, Tarantelli C, Rossi D, Zucca E, Stathis A, Varasi M, Mercurio C, Bertoni F. Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors. **European Journal of Cancer** 2022;174:S108.
20. Arribas A, Chiappa M, Napoli S, Cannas E, Cascione L, Spriano F, Tarantelli C, Rossi D, Zucca E, Alimonti A, Stathis A, Damia G, Brogginini M, Bertoni F. Improving responses to dual PI3K/BCL2 inhibition in lymphomas: results of a pharmacological screen with over 1,400 compounds. **European Journal of Cancer** 2022;174:S107-S8.
21. Wang S, Arribas AJ, Tarantelli C, Pradier A, Zucca E, Rossi D, Simonetta F, Bertoni F. CAR T cells in marginal zone lymphoma (MZL) models with acquired resistance to PI3K and BTK inhibitors. **European Journal of Cancer** 2022;174:S106.
22. Tarantelli C, Civanelli E, Gaudio E, Stathis A, Merlino G, Binaschi M, Bertoni F. The anti-CD205 antibody drug conjugate MEN1309/OBT076 shows synergistic activity in combination with the monoclonal antibody rituximab in diffuse large B cell lymphomas. **European Journal of Cancer** 2022;174:S89.
23. Gaudio E, Tarantelli C, Marques CS, Ekeh H, Carmelo M, Burkner AJ, Bertoni F. N-1,2,3-Triazole-Isatin derivatives in lymphoma cell lines. **European Journal of Cancer** 2022;174:S65.
24. Mensah AA, Valente S, Matkovic M, Sartori G, Falzarano C, Tarantelli C, Cascione L, Pileri SA, Cavalli A, Mai A, Bertoni F. Abstract 3279: Dual inhibition of EZH2 and histone deacetylases for the treatment of lymphomas with epigenetic aberrations. **Cancer Research** 2022; 82 (12\_Supplement): 3279 (AACR 2022).
25. Mensah AA, Chatzigiannis CM, Diamantis DA, Gkalpinos VK, Arribas A, Tzakos AG; Bertoni F. Abstract 3942: Novel BCL2 inhibitors with anti-lymphoma activity. **Cancer Research** 2022; 82 (12\_Supplement): 3942 (AACR 2022).
26. Sartori G, Cascione L, Matkovic M, Matsunami H, Cavalli A, Bertoni F. Abstract 2655: The GPCR OR13A1 is essential for lymphoma cells. **Cancer Research** 2022; 82 (12\_Supplement): 2655 (AACR 2022).
27. Perale G, Gaudio E, Casalini T, Aresu L, De Corso AR, Spriano F, Tarantelli C, Stathis A, Castrovinci A, Bertoni F. Abstract 1879: A novel implantable device to in vivo assess anti-cancer agents. **Cancer Research** 2022; 82 (12\_Supplement): 1879 (AACR 2022).
28. Mensah AA, Sartori G, Falzarano C, Tueckmantel W, A.Kozikowski A, Bertoni F. 11P Novel HDAC6 inhibitors show anti-lymphoma activity alone and in combination with venetoclax and copanlisib. **Annals of Oncology** 2022; 33, (Supplement 1): S7. <https://doi.org/10.1016/j.annonc.2022.01.013>
29. Arribas AJ, Napoli S, Gaudio E, Cascione L, Veroli AD, Tarantelli C, Spriano F, Zucchetto A, Rossi F, Sartori G, Rinaldi A, Stathis A, Stussi G, Gattei V, Cruciani G, Zucca E, Rossi D, Bertoni F. Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma. **Molecular Cancer Therapeutics** 2019, 18, (12 Supplement), A127-A127.
30. Cascione L, Benevento M, Gaudio E, Tarantelli C, Spriano F, Arribas AJ, Rinaldi A, Kwee I, Luecke J, Geiger R, Bertoni F. Analysis of gene and protein expression in lymphoma cell lines using multiple platforms. **Proceedings of the 109th Annual Meeting of the American Association for Cancer Research**. 2018: Abstract 4275
31. Gaudio E, Tarantelli C, Zucca E, Rossi D, Stathis A, Bertoni F. Abstract 4182: The two novel BTK-inhibitors M2951 and M7583 show in vivo anti-tumor activity in pre-clinical models of B cell lymphoma. **Cancer Res** 2017;77(13 Suppl): Abstract nr 4182
32. Arribas A, Gaudio E, Arcaini L, Stathis A, Zucca E, Rossi D, Bertoni F. Targeting the Epigenome and the Cell Signaling As Novel Therapeutic Approaches for Splenic Marginal Zone Lymphoma. **Blood** 2016 128: Abstract 4186.

